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MAPK (mitogen-activated protein kinase) signaling pathways are 
probably the best-characterized signaling pathways in eukaryotic cells. The 
MAPK ERK regulates diverse responses, including cell proliferation, 
differentiation, apoptosis, morphogenetic change and motility. Scaffold 
proteins have been proposed to assemble signal modules and confine MAPK 
signaling molecules at certain sub-cellular localizations to realize efficiency 
and specificity of signal transduction.  Aberrations and mutations in the ERK 
cascade lead to uncontrolled cell growth, and are implicated in a high 
proportion of human cancers.  
In the first part, experimental observations of the endosomal scaffold 
protein MP1 in live cells are described. This work helps motivate the later in 
silico studies of MP1 and MAPK signaling in this thesis. The experiments 
investigate the role of MP1 in MAPK-mediated cell spreading and cytoskeletal 
trafficking. Bioinformatic analysis and live cell imaging are implemented to 
suggest mechanisms scaffold proteins may use to localize ERK signaling and 
regulate focal adhesion turnover. Together with previous work, these 
experiments suggest that scaffold proteins could play essential roles in MAPK 
regulation.   
In the second part, a mathematical model with ordinary differential 
equations is developed to describe the dynamic activation of EGFR-ERK 
signaling under a conventional pathway without scaffolds (EGFR-Ras-Raf-
MEK-ERK), a KSR-scaffolded pathway, and an MP1-scaffolded pathway. 
This work studies the ability of multiple MAPK pathway scaffolds to 
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modulate overall ERK activation. Their effects were examined under the 
influence of the endosomal regulators, Cbl-CIN85 and Endophilin A1.  These 
simulations constitute a multi-dimensional exploration of how EGF-dependent 
ERK activation would be affected by scaffolds KSR and MP1 and their 
functions co-regulated by Cbl-CIN85 and Endophilin A1. Together, these 
results provide a detailed and quantitative demonstration of how regulators 
and scaffolds can collaborate to fine-tune the ligand-dependent sensitivity of 
ERK activation. This might contribute to underlying the differences between 
ERK activation in physiological and pathological conditions.  
Drugs targeting the EGFR-ERK pathway have achieved stunning 
success in controlling initial cancer cell proliferation, but clinical outcomes 
have shown disappointing levels of evolved resistance. Therefore, in the third 
part, a mathematical framework is formulated for investigating evolution of 
resistance in cancer under combined drug inhibition of the EGFR-Ras-Raf-
MEK-ERK pathway. This mathematical framework is applied to investigate 
the dependence of treatment outcomes on the drug interaction type, i.e. 
synergism, additivity, antagonism and super antagonism. Our calculations 
suggest that, within the model assumptions, antagonistic drug combination 
inhibition of MAPK pathway can be more advantageous, especially in cancers 
with low turnover rate. This work therefore gives novel opinions when 
combating with cancer cells: in contrast to traditional strategy seeking 
synergistic drug pairs, we suggest selecting a combination of antagonistic 
drugs targeting the EGFR-ERK pathway. 
In conclusion, this thesis shows how a systems biology approach can 
enhance our understanding of the transmission and propagation of signaling 
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from local immediate effect to system-level and long-term effect. The 
approaches presented here include bioinformatic and experimental analysis 
(Chapter 2), kinetic modeling and quantitative analysis of large regulatory 
networks (Chapters 3 and 4), as well as stochastic modeling of cell evolution 



















List of Tables 
Table 2-1 Surface accessibility area at interface of protein dimers ............. 24 
Table 3-1 A list of sensitive parameters in the pathway model ................... 52 
Table 4-1 Sensitivity analysis of parameters in evolution model .............. 110 
Table 4-2 A list of parameters and variables included in the model .......... 126 
Table 4-3 Proliferation probabilities generated from the EGFR-ERK 
pathway .................................................................................................... 128 
Table 4-4 Proliferation probabilities through targeting of the pathway with 
the same single effect ..................................................................................... 147 
Table 4-5 Assumed proliferation rate in simple Michaelis-Menten kinetics 
with the same single effect ............................................................................. 155 
Table 4-6 Assumed proliferation rate in simple Michaelis-Menten kinetics 




List of Figures 
Figure 2-1 Sequence alignment between 1SKO (MP1/p14 heterodimer) 
and 1Y4O. .................................................................................................. 20 
Figure 2-2 The structure of MP1-p14 complex reveals that MP1 and p14 
share similar structure ...................................................................................... 21 
Figure 2-3 Structure alignment shows large similarity between 1SKO and 
1Y4O .................................................................................................. 22 
Figure 2-4 Structure comparison between IC/LC7 and MP1/p14. ............ 23 
Figure 2-5 Interface comparison of protein dimers. .................................. 23 
Figure 2-6 Colocalization of MP1 and Paxillin. ........................................ 26 
Figure 2-7 The relationship between MP1 and Paxillin expression level. 27 
Figure 2-8 Distribution of MP1 and Paxillin in cells spreading on collagen 
 .................................................................................................. 28 
Figure 2-9 MP1 proteins traffic along microtubules ................................. 30 
Figure 2-10 MP1 traffic together with Rab7 – late endosome marker ........ 31 
Figure 2-11 MP1 does not traffic along actin fibers. ................................... 31 
Figure 2-12 MP1-Rab7 trafficking under 100ng/ml EGF stimulation at 
different time points ......................................................................................... 32 
Figure 2-13 Western blot of EGF stimulated ERK activation in HeLa JW 
cells transfected with MP1 plasmid ................................................................. 33 
Figure 2-14 Localization of ERK after EGF stimulation for 10 min .......... 34 
Figure 3-1 Normalized parameter sensitivities toward the time integral of 
ppERK in 1000 seconds ................................................................................... 52 
Figure 3-2 ERK activation profiles from 100 random models. ................. 54 
Figure 3-3 The distribution of the integrated ppERK from 1000 random 
models .................................................................................................. 54 
Figure 3-4 The percent of perturbed models that have output levels 
(integrated ppERK) within a given percent range of the original output ........ 55 
Figure 3-5       Pathway model used in this study. ........................................... 58 
xii 
 
Figure 3-6 The detailed biochemical model of scaffolding action of KSR. .. 
 .................................................................................................. 59 
Figure 3-7 The detailed biochemical model of scaffolding action of MP1. .. 
 .................................................................................................. 60 
Figure 3-8 The biphasic effect of KSR concentration on ERK activation. ... 
 .................................................................................................. 62 
Figure 3-9 The profile of active ERK before and after p14 knockout. ...... 63 
Figure 3-10 The biphasic effect of MP1 concentration on ERK activation.64 
Figure 3-11 A three-dimensional plot of time integral of ppERK with 
respect to KSR and MP1 level variation. ......................................................... 65 
Figure 3-12 The collective effect of KSR and MP1 on ERK activation. .... 68 
Figure 3-13 The synergistic effect of the two membrane associated 
signaling components....................................................................................... 72 
Figure 3-14 Contribution of individual modules to the overall ERK 
signaling at various EGF concentrations. ........................................................ 73 
Figure 3-15 Sensitivities of individual subpathways when both scaffold 
proteins are at low level. .................................................................................. 75 
Figure 3-16 Sensitivities of individual subpathways when both scaffold 
proteins are at optimal level. ............................................................................ 76 
Figure 3-17 Detailed analysis of sensitivities of ppERK from individual 
subpathways mediated by scaffold proteins under various situations. ............ 78 
Figure 3-18 Detailed analysis of the sensitivities of endocytosed EGFR 
mediated by scaffold proteins under various situations. .................................. 80 
Figure 3-19 Hypothesized model: the distinct dynamics of ERK activation. . 
 .................................................................................................. 82 
Figure 4-1 Normalized parameter sensitivities toward the time integral of 
ppERK in 7200 seconds ................................................................................. 109 
Figure 4-2 The selected dose-normalized ED50 isobolograms of 
combination therapies targeting the EGFR-Ras-Raf-MEK-ERK pathway. .. 120 
Figure 4-3 The example classic ED50 isobolograms for two drugs with 
actual doses on the x- and y- axis. ................................................................. 121 
Figure 4-4 Workflow of the systematic procedure to simulate cancer cell 
evolution under drug combination treatment ................................................. 124 
xiii 
 
Figure 4-5 Evolution patterns of cancer cells under four different NCE 
treatments ................................................................................................ 127 
Figure 4-6 Evolution patterns of low-turnover cancer cells under four 
different NCE treatments ............................................................................... 133 
Figure 4-7 Evolution patterns of cancer cells with very low turnover rate 
under four different NCE treatments ............................................................. 135 
Figure 4-8 Diagram of the relationship between the speed of resistance 
evolution and cancer cell turnover rates ........................................................ 137 
Figure 4-9 Diagram of the relationship between the time to DM 
dominance and cancer cell turnover rates ...................................................... 141 
Figure 4-10 Diagram of the relationship between the total cell number after 
500 generations and cancer cell turnover rates .............................................. 143 
Figure 4-11 The dose-normalized ED50 isobologram of two redundant drugs 
targeting MEK in the EGFR-ERK pathway .................................................. 146 
Figure 4-12 Evolution patterns of cancer cells under three NCE treatments 
on the pathway with the same single effect ................................................... 149 
Figure 4-13 Statistics on resistance evolution dynamics for cancer cells 
under NCE treatments on the pathway with the same single effect .............. 151 
Figure 4-14 Evolution patterns of cancer cells under assumed drug 
treatments with the same single effect ........................................................... 156 
Figure 4-15 Evolution patterns of cancer cells under assumed drug 
treatments with the same combined effect ..................................................... 158 
Figure 4-16 Evolution patterns of cancer cells under four NCE treatments 
in exponential growth model ......................................................................... 160 
Figure 4-17 A comparative study of simultaneous and sequential targeting 










List of Abbreviations 
Cbl E3 ubiquitin-protein ligase Cbl 
CIN85 Cbl-interacting protein of 85 kDa 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
EP Endophilin A1 
ERK Extracellular signal-regulated kinases 
GPCR G protein coupled receptors 
KSR Kinase Suppressor of Ras 
MEK Mitogen-activated protein kinase kinase 
MEKK1 MEK kinase 1 
MKP3 MAP Kinase Phosphatase 3 
MKPs MAP Kinase Phosphatases 
MP1 MEK Partner 1 
PI3K Phosphatidylinositol 3-kinases 
PP2A Protein phosphatase 2 
PTEN Phosphatase and tensin homolog 
Raf RAF proto-oncogene serine/threonine-protein kinase 
Rap1 Ras-related protein 1 
Ras a protein subfamily of small GTPases 
RhoA Ras homolog gene family, member A 
RhoGAP Rho GTPase activating proteins 
RhoGEF Rho guanine nucleotide exchange factors 
RKIP Raf-1 kinase inhibitor protein 
ROCK Rho-associated protein kinase 
SHP2 Src homology region 2 domain-containing phosphatase-2 
SOS Son of Sevenless 








Chapter 1 General Introduction 
1.1 Signal transduction from the cell 
surface to the nucleus 
Extracellular signals such as growth factor stimulations are transmitted 
from cell membrane to the nucleus through intracellular signaling networks. 
The signal is typically transmitted and amplified through layers of enzymatic 
cascades, from the cell membrane to the nucleus, and ultimately leads to 
multiple cellular responses like morphological change and cell fate decisions, 
etc.  
One of the most classical and widely studied signaling networks is the 
MAPK cascade in biological systems, which governs cell proliferation, growth, 
apoptosis, differentiation and survival of many cell types. The deregulation of 
the MAPK pathway has been implicated in various immunological and 
inflammatory diseases and cancers (Chang and Karin 2001; Huang, Jacobson 
et al. 2004; Zheng, Han et al. 2006). Many emerging therapies emphasize 
targeting proteins in this pathway. More than a dozen drugs in clinical trials, 
including humanized antibodies and small molecule inhibitors, are developed 
to target the upstream pathway and the core MAPK module (Sebolt-Leopold 
2000; Giusti, Shastri et al. 2007). 
Although the basic network structure and reactions of the MAPK 
module containing Raf, MEK, and ERK are well understood, it remains 
unclear how MAPK pathway achieves the diverse outcomes. ERK activation 
can elicit various outcome signals, the output signal profiles can be either 
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transient or sustained depending on different dynamics among growth factor 
receptors (Di Fiore and Gill 1999), magnitude regulators (Therrien, Michaud 
et al. 1996; Teis, Wunderlich et al. 2002), and various anchor proteins (Torii, 
Kusakabe et al. 2004). This cannot be completely explained by cell type 
specificity because ERK activation has diverse outcomes even in the same cell 
type (Schaeffer and Weber 1999; Tan and Kim 1999). 
1.2 Various regulators of the MAPK 
pathway contribute to the specificity of outputs 
Collective regulation by different combinations of direct regulators, 
positive and negative feedbacks, scaffold proteins, and pathway crosstalk 
enable MAPK to generate a wide range of cell-type, disease and drug specific 
signalling responses, such as receptor-selective signalling, oscillations, gradual 
and ultrasensitive responses (Schaeffer and Weber 1999; Markevich, Hoek et 
al. 2004; Ebisuya, Kondoh et al. 2005; Dhanasekaran, Kashef et al. 2007; 
Goldsmith and Dhanasekaran 2007). For instance, the altered expression of 
MAPK regulatory proteins KSR1 (Kim, Yan et al. 2005; Stoeger and Cowan 
2009) and RKIP in fibroblast, melanoma, prostate and breast cancer cells 
correlates with the altered level of proliferation and anticancer drug efficacies 
(Chatterjee, Bai et al. 2004; Park, Yeung et al. 2005). Differential expression 
and activities of multiple MKPs significantly alter proliferation and resistance 
to anticancer drugs (Owens and Keyse 2007). Some MAPK regulators convey 
signals from other pathways into MAPK, e.g. beta-arrestins link GPCRs with 
MAPKs, and Paxillin coordinates MAPKs in cell migration and survival with 
cell adhesion, cytoskeletal reorganization (Ma and Pei 2007).  Paxillin down-
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regulation in lung cancer cells correlates with metastatic cancer, but its 
upregulation in prostate epithelium and renal carcinoma correlates with 
metastatic cancer (Deakin and Turner 2008). Another regulator of MAPK 
signalling is mTOR Complex 1, whose inhibition leads to MAPK activation 
via a PI3K-dependent feedback loop in prostate and breast cancer (Carracedo, 
Ma et al. 2008). The combined inhibition of EGFR and mTOR in lung cancer 
cells synergistically overcomes resistance against individual inhibitors 
(Settleman and Kurie 2007).  
Moreover, intricate systems have been developed in cells, providing 
them with the capability to translocate MAPK components to specific 
microenvironments in response to a particular stimulus (Inder and Hancock 
2008). Ubiquitously expressed in almost all mammalian cell types, scaffold 
proteins cause assembly, coordination, and localization of signaling-competent 
complexes, critical for generation of distinct system output through 
compartmentalized signaling. They also insulate signaling molecules from 
deactivation enzymes (Shaw and Filbert 2009), which is beneficial for the 
continuity of signal transmission.  
One character of scaffold proteins is that the following: The signaling 
is increased in a concentration-dependent manner when scaffold concentration 
is increased, up to an optimum level at which all scaffold proteins are fully 
occupied with kinases. However, further increase of scaffold concentration 
leads to decreased signaling due to the existence of incomplete scaffold 
proteins with individual kinases (Ferrell 2000). 
4 
 
1.3 MAPK signaling is important for cell 
proliferation in normal and cancer cells 
Cell proliferation regulation in multicellular organism is a complex 
process, which is strongly regulated by external growth factors. Among them, 
The EGF-stimulated MAPK pathways, involving a series of protein kinase 
cascades, play a critical role in regulation of cell proliferation and survival. As 
is shown in several studies, interfering with components of the ERK signaling 
pathway such as Raf-1 or ERK1 shows significant inhibition of cell 
proliferation. In contrast, stimulating ERK1 activity results in enhanced cell 
proliferation (Seger and Krebs 1995; Widmann, Gibson et al. 1999). It was 
demonstrated that in PC12 cells, transient Ras/Raf signal induces cell 
proliferation whereas a sustained activation causes these cells to differentiate 
and slowly ceases the cell cycle (von Kriegsheim, Baiocchi et al. 2009). All 
these data demonstrated that the ERK cascade plays an essential role in the 
control of cell cycle progression and cell proliferation. 
Aberrations and mutations in the ERK cascade lead to uncontrolled 
cell growth, as seen in a high proportion of human cancers. For example, 
hyperactivity of EGFR in tumor cells can trigger a series of intracellular 
events resulting in enhanced cell proliferation, blocked apoptosis, invasion and 
metastasis, which are the main characteristics of cancer (Ciardiello and 




1.4 The quantitative model of signaling 
pathway gives insight into cell dynamics 
A major challenge in signal transduction research is to unravel the 
complicated organization and collective interactions in protein networks. 
Cellular signal transduction pathways composed of various signaling modules 
and regulators are essential for cells to conduct complex life processes. 
Through receiving signals from the environment, cell surface receptors are 
activated and then transmit the information to downstream effectors to achieve 
certain cellular responses.  
A qualitative conceptual model is commonly used as a simplification 
and representation of a complex system by experimentalists to make intuitive 
hypotheses and predictions about how two species might be related. Owing to 
the complexity of biological systems, more complicated quantitative models 
are implemented to gain insights into how extracellular signals are integrated 
and how cell decisions, e.g. proliferation or apoptosis, are made and controlled. 
A quantitative model of a signaling pathway describes the relationships among 
species through a series of mathematical equations, and gives explanations of 
non-intuitive experimental phenomena, and formalizes hypotheses based on 
known data. 
Over the decades, mathematical modeling studies have provided a 
system-level understanding of cellular signaling networks. One of the most 
characterized pathways, MAP kinase signaling, has been repeatedly studied in 
systems biology, since Huang and Ferrell pioneered the development of 
mathematical models of the MAPK pathway. For example, ultra-sensitivity 
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was revealed through analyzing this quantitative pathway(Huang and Ferrell 
1996). Quantitative mathematical modeling is a powerful tool for reducing 
system complexity, investigating useful regulatory principles and identifying 
key parameters that determine cell dynamics. It helps to validate biological 
hypotheses, facilitate experimental design and give insight into cell signaling 
networks. 
 
1.5 Objectives and outline of this work  
Although regulation of the MAPK pathway is extensively studied 
experimentally and computationally, there are still challenges unsolved: 
(1) Many putative ERK scaffolding proteins have been proposed to 
contribute to MAPK signaling specificity and efficiency by assembling signal 
modules and confining signaling molecules at certain subcellular localizations. 
However, none of these scaffold proteins has been linked to a specific 
biological process or system outcome. 
(2) Despite the functional significance of scaffold proteins, there are no 
systematic models studying ERK pathway and scaffold regulation. The 
detailed dynamics and functional consequences of the coordinated actions of 
multiple scaffold proteins remain to be fully elucidated. Quantitative study of 
the effects on ERK signaling by these scaffold proteins and other regulators in 
a systematic way is needed in order to have a comprehensive understanding of 
whether they exert their roles in isolation or in concert during cell signaling 
dynamics, disease manifestation and drug response.  
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(3) There are no investigations of evolution of cancer cell resistance 
under combined inhibition of the EGFR-ERK pathway. As a clinically 
important pathway, protein species in the MAPK network provide many 
essential clinical drug targets for treatment of cancer. Synergistic combination 
therapy targeting this pathway has been employed as a strategy for cancer 
treatment for the higher than additive efficiency. However, bacterial evolution 
research found that synergistic drug pairs accelerated resistance evolution in 
bacteria; it is of interest to examine whether there is a similar effect for 
synergistic drug combinations in cancer. In particular, the selection of drug 
targets in this pathway, and the different effects of drug combination scheme, 
i.e. synergism, additivity, or antagonism, on cancer cell resistance evolution 
remain to be examined systematically. 
In order to better understand the dynamic behavior of scaffold-
mediated MAPK networks in response to ligand and inhibitors, this thesis is 
aimed to:  
1. Investigate the spatiotemporal dynamics of ERK scaffold protein 
MP1/p14 in a specific cellular process, such as cell spreading and 
intracellular trafficking, through live cell imaging.  
2. Construct computational pathway models for the EGFR-Ras-Raf-
MEK-ERK pathway with modules mediated by membrane targeted 
scaffold protein KSR and late endosome targeted scaffold complex 
MP1/p14. The known inflow of KSR/MP1 into ERK pathway is 
taken to combine and predict the individual and collective 
dynamics of ERK signalling dynamics from systems level. 
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3. Examine the diverse resistance evolution patterns of cancer cells 
when treated with different drug combinations through stochastic 
mathematical modelling. Specifically, it is simulated whether the 
bacterial evolution effect occurs also in cancer with ERK drugs, 
and whether the speed of resistance evolution is dependent on drug 
synergism. 
In summary, this work is aimed at investigating signal network 
regulation. More specifically, the study seeks to predict and characterize 
pathway dynamics regulated by scaffold proteins and furthermore the 
evolution dynamic by dual inhibition of the pathway species. The present 
study may shed some light on the specific role of the scaffold proteins in 
certain cell processes, and could help in the selection of novel therapy 
methods to combat cancer cell resistance. 
The complete outline of this thesis is as follows: In Chapter 1, a 
general background is described to introduce the signalling pathway and 
dynamic modelling. The properties of scaffold proteins are defined. 
Specifically, it is presented that seeking drugs targeting the EGF induced 
MAPK pathway is important.  
Chapter 2 describes a preliminary exploration of the role of MP1/p14 
using live cell imaging. In particular, it is investigated how the spatiotemporal 
dynamics of MP1/p14 change in cell spreading and intracellular trafficking.  
Bioinformatic analysis on sequence and structure of MP1 is also performed. 
In Chapter 3, the second part of the project is described, which focuses 
on scaffold-mediated MAPK Pathway simulation. The theoretical background 
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of this project, and the model construction are depicted as well. Furthermore, 
sensitivity analyses on three distinct subpathways mediated by scaffold 
proteins are presented in detail. 
In Chapter 4, double drug inhibition of the pathway is introduced by 
evaluating the drug effect at the system-level. A mathematical framework was 
built that can be used to study the underlying principles of the emergence and 
evolution of resistance in cancers. Combinations of drugs with different 
interaction types are applied in this mathematical framework, and simulations 
of stochastic evolution process are conducted. 
Finally, in the last chapter, Chapter 5, major findings and contributions 
of current work to the progress of pathway regulation mechanism and cancer 
therapy are discussed. Limitations and suggestions for future studies are also 












Chapter 2 Exploring the role of 
endosomal scaffold for MAPK signaling in 
cell spreading and trafficking 
 
Parts of this chapter have been presented at the SMA-CSB symposium. 
2.1 Abstract 
MAPK (mitogen-activated protein kinase) signaling pathways are 
probably the best-characterized signaling pathways in eukaryotic cells. The 
signal from cell surface receptors to intracellular response is connected 
through the hierarchically organized three-tiered modules. MAP3Ks (e.g. Raf) 
phosphorylate and activate MAP2Ks (e.g. MEK), which in turn phosphorylate 
and activate MAPKs (e.g. ERK).  
One challenging question is how this MAPK pathway can achieve 
versatile signaling dynamics that leads to specific cellular responses. Scaffold 
proteins are proposed to assemble signal modules and confine signaling 
molecules at certain subcellular localizations to realize efficiency and 
specificity of signal transduction. For example, as a small scaffold protein, 
MP1/p14 is suggested to confine and promote ERK signaling on late 
endosomes upon EGF stimulation. 
The trafficking and distribution of intracellular organelles (e.g. 
endosomes) has been discovered to contribute to cell responses involving 
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volume and membrane area change, such as cell spreading. Through 
bioinformatics analysis, it is found there is structural analogy between 
MP1/p14 and Roadblock/LC7 dynein light chain homodimer. This structural 
similarity suggests MP1/p14 might have trafficking function as the dynein 
complex, which can be used to localize ERK signaling and regulate focal 
adhesion turnover. Therefore, the main goal in this chapter is to identify the 
possible role of MP1/p14 in cell spreading. Using live cell imaging, it is 
feasible to monitor the movement and distribution of MP1/p14 and focal 
adhesion protein (e.g. Paxillin) during and after cell spreading.  
Moreover, it is found that, upon EGF stimulation, the time scale of 
trafficking of MP1/p14 is consistent with the temporal activation of ERK. This 
indicates scaffold protein MP1/p14 might have the role of coordinating the 
spatial distribution and activation of ERK in response to EGF.  
2.2 Introduction 
2.2.1 Endosomal signaling mediated by scaffold protein 
MP1/p14 is essential for proper ERK activation 
Scaffold proteins have been proposed to mediate the versatility and 
specificity of cell signaling because of their capability of assembling signaling 
molecular together, localizing signaling modules to specific 
microenvironments, coordinating positive and negative feedback loops, and 
insulating signaling molecules from other pathways. There are many putative 
scaffold proteins that have been discovered inside cells. Scaffold proteins in 
the same network sometimes work in close cooperation with an appropriate 
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division of labor, as will be investigated in our mathematical modeling 
analysis of KSR (Kinase suppressor of Ras) and MP1 (MEK Partner 1) 
mediated MAPK activation in Chapter 3. In particular, MEK Partner 1 (MP1) 
is a widely expressed small scaffold protein that is recruited to late endosomes 
by the adaptor protein p14, where it promotes the assembly and interaction of 
MEK1 and ERK1. And, upon stimulation by the internalized activated cell 
surface receptors that are trafficked to the late endosomes (Nada, Hondo et al. 
2009), it facilitates Ras activation of the MEK1-ERK1 module there 
(Morrison and Davis 2003; Kolch 2005; Teis, Taub et al. 2006; Nada, Hondo 
et al. 2009). MP1/p14 is a scaffold protein complex that specifically targets 
MEK1 and ERK1 onto late endosomes, which participate in the later phase of 
ERK activation and contribute to sustained ERK signal. Endosomal signaling 
of ERK mediated by MP1/p14 is important for proper cell processes such as 
cell signaling, cell spreading and intracellular trafficking. 
Moreover, it has been shown that only when correctly localized on late 
endosomes, MP1/p14 can contribute to the later phase of ERK signaling (Teis, 
Wunderlich et al. 2002) (Figure 2-5), while disruption of MEK1-MP1-p14 
complex will cause mislocalization of late endosomes and lead to deficiency 
in MAPK signaling transmission (Teis, Taub et al. 2006) . This indicates that 




2.2.2 Endosomal ERK signaling in cell spreading 
regulation: the functions of MP1/p14 and Rho, ROCK 
ERK activity is found to be required for the disassembly and 
remodeling of focal adhesions (Webb, Donais et al. 2004). Upon extracellular 
matrix stimulation, active ERK will be translocated to focal adhesions 
(Roberts, Woods et al. 2003), and stimulates the disassembly of focal adhesion 
structures (Webb, Donais et al. 2004). One of the downstream effector 
proteins of ERK is Rho, which is actively involved in the regulation of focal 
adhesions. Specifically, Rho regulates the assembly of stress fibers and focal 
adhesions through its downstream effector ROCK and counteracts membrane 
protrusion induced by Cdc42 and Rac (Raftopoulou and Hall 2004).  ERK was 
found to oppose Rho function as suggested by the upregulated ROCK activity 
in cancer cells when treated with ERK signaling inhibitors (Vial, Sahai et al. 
2003), thus promoting the remodeling of focal adhesions. 
Interestingly, only sustained rather than acute ERK signaling is found 
to be capable of downregulating Rho/ROCK function (Vial, Sahai et al. 2003). 
It is known that sustained ERK signaling is usually transmitted through 
endosomal scaffold protein MP1/p14. Furthermore, in MP1/p14 knockdown 
REF52 cells ROCK (Rho effector) was found to be upregulated, and the lack 
of MP1/p14 caused deficiency on cell spreading on fibronectin or vitronectin 
(Pullikuth, McKinnon et al. 2005). Based on these knowledge, it is possible 
that it might be endosomal scaffold MP1/p14 that were taking a role in 




Although there are many putative scaffold proteins being identified in 
MAPK pathway, none of them have been studied for long-term effect and 
linked to a specific biological process. The previous knowledge and studies as 
stated above give us a hint that endosome localized scaffold protein MP1/p14 
might be involved in cell spreading process, however, the evidence is not yet 
sufficient to have a conclusive statement about the role of MP1/p14 in cell 
spreading. 
It has been shown that the increase of plasma membrane area during 
cell spreading might be regulated by endocytosis and exocytosis of 
intracellular compartments (Gauthier, Rossier et al. 2009), which requires 
active trafficking of intracellular organelles along microtubules or actin fibers. 
The trafficking of the endosomes, the organelle on which scaffold protein 
MP1/p14 localizes, might contribute to the change of plasma membrane area 
during cell spreading. Together with the fact that a crystal structure of 
MP1/p14 was found similar to the Roadblock/LC7 dynein light chain 
homodimer (Ilangovan, Ding et al. 2005), it raises the speculation that 
MP1/p14 may be able to mimic some dynein components and be assembled in 
dynein complex.   
Therefore, the hypothesis of this work is that MP1/p14 might regulate 
cell spreading through its influence on dynamic trafficking and division of 
signaling modules to specific subcellular localizations, e.g. late endosomes.  
In this work, in order to identify the role of MP1/p14 in endosomal 
trafficking and cell spreading, several experiments were conducted. On one 
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hand, bioinformatic analysis was performed based on known structure and 
sequence information of MP1/p14, and compared them to motor proteins, e.g. 
some dynein components. On the other hand, the colocalization and 
distribution of MP1/p14 with focal adhesion proteins (e.g. Paxillin) during cell 
spreading were monitored, through immunofluorescence and live cell imaging. 
It was also examined how is the coordination between spatial distribution of 
MP1/p14 and ERK activation upon EGF stimulation.  
2.3 Materials and methods 
2.3.1 Bioinformatics 
To quantify sequence similarity, alignment of two sequences is 
performed by using the “align” function in UniProt. In this Smith-Waterman 
algorithm based local alignment, amino-acid residue matches, mismatches or 
gaps are scored and recorded in a substitution matrix, and the optimal local 
alignment is determined by the resulted optimal similarity score. 
The structural comparison is performed by using the “super” function 
in PyMOL. A least-squares fitting algorithm is used, in which the program 
searches for the optimal superposition of atomic coordinate sets by minimizing 
the RMSD (root mean square deviation) between the structures. 
The interface residue between two proteins or chains is found by 
comparing the chain-only surface area and complex-based areas. If the result 




The solvent-accessible surface area (SASA) of interface residue is then 
measured by calculating the surface area of the selected interface residues. It is 
based on the Lee & Richards (1971, J. Mol. Biol., 55, 379-400) method, which 
hypothesizes a probe of given radius rolling around the Van der Waals surface 
of the molecule, and the path traced out by its centre is the solvent accessible 
surface. The buried surface area of a dimer was then determined through 
calculating the sum of the SASA of the individual monomer and subtracting 
this value from the SASA of the dimer. The probe radius is set as 1.4 
Angstroms, the radius of a water molecule. 
2.3.2 Plasmid construction and antibodies 
The pCMV6-AC-GFP-MP1 was purchased from Origene. The 
mcherry-Rab7, were kindly provided by Dr. Yiting Zhou, Mechanobiology of 
Singapore. The plasmids RFP-EB3 and RFP-LifeAct were kindly provided by 
Dr. Yee Han Tee, Mechanobiology Institute of Singapore. pEGFP-C1-EGFP-
ERK1 was obtained from Addgene. 
Primary antibodies were used according to the manufacturer's 
instructions. The primary antibodies used were polyclonal anti-Flag and 
monoclonal phospho-ERK1/2 (Sigma), polyclonal anti-HA and polyclonal 
anti-α-tubulin (Invitrogen), polyclonal anti-ERK1/2 (Cell Signaling), 
polymonoclonal anti-Paxillin antibody (BD Biosciences). Anti- MP1 antibody 
was purchased from Santa Cruz Biotechnology. 
The Alexa 488, Alexa 568, and Alexa 647 secondary antibodies were 
obtained from Invitrogen. 
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2.3.3 Cell culture and transfection 
Secondary cell lines originally obtained from The American Type 
Culture Collection (ATCC) were used in this thesis. They were grown, 
maintained and manipulated according to the general regulations stipulated for 
the Biosafety Level 2 (BSL2). HeLa JW cells were grown in high-glucose 
DMEM (Hyclone) with 10% (v/v) fetal bovine grown at 37
o
C, 5% CO2. 
2.3.3.1 Transfection 
Cells were transfected at 60-80% confluency in 35mm plates (6-well 
plates). HeLa JW cells were transfected with Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instruction. 
2.3.3.2 EGF stimulation of cells 
Cells were washed three times with serum-free medium and made 
quiescent by the same medium for 16-24 h hours before stimulation with 100 
ng/ml of EGF (Epidermal growth factor) for the indicated times. 
2.3.4 Western blot analysis 
Protein samples were added with 1/5 volume of 6X loading buffer [3% 
(w/v) SDS, 15% (v/v) glycerol, 7.5% (v/v) β-mercaptoethanol, 0.1 M Tris-HCl 
pH 6.8, 0.005% (w/v) bromophenol blue] and boiled at 85
o
C for 5 min. The 
denatured proteins were separated by 12% SDS-polyacrylamide gels (SDS-
PAGE). The separating gel contained 12% (w/v) acrylamide, 0.48% (w/v) N-
N‟-methylbisacrylamide, 0.375mM Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.0075% 
(w/v) AMPS and 0.05% (v/v) TEMED. The stacking gels contained 4% (w/v) 
acrylamide, 0.133% (w/v) N-N’-methylbisacrylamide, 0.125 mM Tris-HCl pH 
18 
 
6.8, 0.1% (w/v) SDS, 0.0075% (w/v) AMPS and 0.08% (v/v) TEMED. Gel 
electrophoresis was performed at 50mA/gel for 1 hour at room temperature in 
SDS-running buffer [25 mM Tris, 192 mM glycine and 0.75% (w/v) SDS]. 
The separated proteins were transferred from the gel onto PVDF membrane 
(Bio-Rad Laboratories) in transfer buffer [33.7 mM Tris, 256 mM glycine, 20% 
(v/v) methanol and 0.01% (w/v) SDS] at 100 Volt for 1 hour at 4
o
C. The blots 
were blocked with buffer containing 1% BSA, 0.1% Tween-20 in PBS at room 
temperature for 1 hour and subsequently incubated with primary antibody 
diluted in blocking buffer at 4
o
C overnight. The blots were then washed thrice 
with 0.1% Tween 20 in PBS at room temperature for 10 min. The blots were 
then incubated with secondary antibody conjugated with horseradish 
peroxidase (Sigma-Aldrich) diluted at 1:3000 in PBS with 0.1% Tween-20 for 
1 hour at room temperature and washed thrice with 0.1% Tween-20 in PBS at 
room temperature for 10 min. The signals were generated by using Pierce Pico 
ECL kit (Thermo Scientific).  
2.3.5 Immunofluorescence 
HeLa JW cells grown on sterilized glass cover slips 24 hours post 
transfection were fixed with formaldehyde in PBS for 15 minutes at room 
temperature. Fixed cells were washed three times with PBS, permeabilized 
with 0.2% Triton X-100 (BioRad) in PBS for 15 minutes at room temperature 
and blocked with 2% bovine serum albumin and 7% fetal bovine serum in 
PBS for 1 hour. Cells were incubated with 40 μl of blocking buffer containing 
primary antibodies in combination as indicated for 1 hour at 37
o
C. Samples 
were washed three times with PBS containing 0.1% Triton X-100 and 
incubated with secondary antibodies for 1 hour at room temperature. The 
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cover slips were washed thrice with PBS containing 0.1% Triton X-100 before 
mounting with FluorSave (Calbiochem) and examined with Nikon A1Rsi 
confocal microscope using 100X oil immersion lens. 
2.3.6 Cell spreading assay and trafficking assay 
HeLa JW cells were transfected with MP1-GFP and Paxillin-RFP 
plasmids, and were cultured for protein expression overnight in 0% FBS 
medium. After that, the cells were trypsinized and washed three times using 0% 
FBS medium. The transfected HeLa JW cells were then placed on glass 
bottomed wells (24-well Transwell plates; coated with 10 μg/ml collagen 
(Invitrogen) with 1 ml medium with 0% FBS. The spreading process was 
captured after cells attach to collagen by live cell imaging under a Spinning-
Disc confocal microscope. 
Transfected HeLa JW cells were placed on glass bottomed wells 
(35mm, ibidi), after starvation by 0% FBS medium for 16-24 hours, 100 ng/ml 
of EGF was then added to wells, and observed for intracellular protein 
trafficking under Spinning-Disc confocal microscope. Videos and images are 
taken every 5 min. 
2.4 Results 
2.4.1 Structure, sequence and surface accessibility 
comparison between MP1/p14 and Roadblock/LC7 dynein 
light chain homodimer  
Since an crystal structure of MP1/p14 was found similar to the 
Roadblock/LC7 dynein light chain homodimer (Ilangovan, Ding et al. 2005), 
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it raises the speculation that MP1/p14 may be able to mimic some dynein 
components and be assembled in dynein complex. Cytoplasmic dynein is a 
large complex that functions as a motor protein transporting cargo to the 
minus end of microtubules, and is involved in many cellular functions, 
including mitosis, vesicle transport and organelle positioning, etc. So we ask 
whether MP1/p14 will have similar transporting or trafficking capabilities as 
dynein, thereby influencing intracellular mobility of signaling endosomes. The 
investigation was started with some bioinformatic analysis of the homology 
between MP1/p14 and Roadblock/LC7, focusing on sequence, structure and 
surface accessibility. 
 




Sequence alignment between 1SKO (MP1/p14 heterodimer) and 1Y4O 
(Roadblock/LC7 dynein light chain dimer) shows there are 34 identical 





Figure 2-2 The structure of MP1-p14 complex reveals that MP1 and 
p14 share similar structure 
The complex of MP1/p14 is a heterodimer, 1SKO is the crystal structure of 
MP1-p14 complex, data obtained from X-ray diffraction with resolution of 






Figure 2-3 Structure alignment shows large similarity between 1SKO 
and 1Y4O 
Structure alignment shows large similarity between 1SKO (MP1/p14 
heterodimer) and 1Y4O (Roadblock/LC7 dynein light chain dimer).  RMSD = 
5.906 Angstroms (729/297 atoms). The green chain A represents MP1, the 
blue chain B represents p14, and the purple chain is Roadblock/LC7 dimer 
(Solution structure of a mouse cytoplasmic Roadblock/LC7 dynein light 
chain). 
 
The dynein complex is composed of several subunit classes: light 
chains (LC), light intermediate chains (LIC), intermediate chains (IC), heavy 
chains (HC) (Kardon and Vale 2009). The dynein light intermediate chain 
(LIC) and intermediate chain (IC) directly associate to the dynein heavy chain. 
The intermediate chain (IC) functions as a scaffold protein for light chains 
including LC8 (light chain 8), LC7 (light chain 7, also known as Roadblock 
family) and TCTEX1 (T-complex testis-specific protein 1) to assemble on, 
and the light chains are suggested to interact directly with dynein adaptor 
proteins and are essential for dynein heavy chain localization (Beckwith, 




Figure 2-4 Structure comparison between IC/LC7 and MP1/p14. 
(A) Structure of IC/LC7 dimer, the purple chain is Roadblock/LC7 dynein 
light chain dimer, the blue and orange chain is part of IC (dynein intermediate 
chain); (B) Alignment of IC/LC7 to MP1/p14: The green chain A represents 
MP1, the blue chain B represents p14, the purple chain is Roadblock/LC7 
dimer, and the blue and orange chain is part of IC (dynein intermediate chain). 








Figure 2-5 Interface comparison of protein dimers. 
Interfaces of protein dimers: (A) the red and yellow colored parts are interface 
residues of 1SKO, heterodimer of mp1 (green chain) and p14 (blue chain); (B) 
the red and yellow colored parts are interface residues of 1Y4O, homodimer of 
Roadblock/LC7 (purple chain). 
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Table 2-1 Surface accessibility area at interface of protein dimers 





H F TF LA QG 
KLGLSKNKSII
CYYNTY 
Q S TG V  
1sko_mp1 interface 
solvent accessibility 
68.83 41.33 76.66 148.45 140.31 1568.16 13.01 39.15 68.04 43.68  
1sko_p14 interface 
residues 
DT T IA NI AY 
EDSLKFILMDC
MEG 
V C Y F K 
1sko_p14 interface 
solvent accessibility 
219.27 34.12 91.47 134.27 236.61 1107.52 27.38 0.56 55.46 82.75 75.89 
1Y4O_chain A 
interface residues 
H QY LM F KA TV EI 
QNDLTFLRIR
SKKN 




165.13 201.63 146.87 95.95 116.47 130.94 248.25 1328.6 17.44 38.66 209.72 
1Y4O_chain B 
interface residues 
HH QY LM F KA TV EI 
QNDLTFLRIR
SKKN 




281.8 207.55 145.75 96.45 124 134.5 265.91 1283.02 16.78 67.81 164.78 
25 
 
Although they do not share large sequence similarity (Figure 2-1), 
crystal structure alignment reveals striking similarity among MP1, p14 and 
Roadblock/LC7 dynein light chain (Figures 2-2 and 2-3). They both have five 
β-strands and three α-helices in their structures, but a major structural 
difference is that LC7 lacks an amphipathic C-terminal helix (α3) that is 
present in MP1/p14. Interestingly, by assembly complex of LC7 (dynein light 
chain 7) and IC (intermediate chain), IC completes their fold topology to be 
more like its homolog MP1/p14 through adding a helix to the LC7 structure 
(Figure 2-4). The observation is that IC adds an α3 helix to the LC7 fold to 
make it more similar to its homolog MP1/p14. 
Furthermore, the interface residues of the MP1/p14 heterodimer and 
Roadblock/LC7 homodimer are identified and it is find that the interface 
residues, spatial positions and respective solvent accessible surface area at the 
dimer interface are one-to-one corresponding with each other (Figure 2-5 and 
Table 2-1). In both dimer complexes, the solvent accessible surface area of the 
interface contains 10 scattered residues on the alpha helices and 1 continuous 
residue sequence on the beta sheets on each chain (Figure 2-5). The total 
solvent-accessible surface area buried upon complex formation in 1SKO is 
2400.8 square angstroms (Å²) and in 1Y4O is 2780.4 square angstroms (Å²), 
respectively. These areas are comparable and suggest a possibility of match of 








Figure 2-6 Colocalization of MP1 and Paxillin. 
Colocalization of MP1 and Paxillin in well spread HeLa JW cells on collagen. 
This is a montage of z stacks from bottom to top of the cell. (A) Merged 






Figure 2-7 The relationship between MP1 and Paxillin expression 
level. 
(A) Western blot of Paxillin level in HeLa JW cells overexpressed with MP1. 
Lane 1: MP1-overexpressed HeLa JW cell lysate 1; Lane 2: MP1-
overexpressed HeLa JW cell lysate 2; Lane 3: MP1-overexpressed HeLa JW 
cell lysate 3; Lane 4: wildtype HeLa JW cell lysate. (B) Graph of MP1 and 
Paxillin level in cell samples, the protein level is normalized to housekeeping 




Figure 2-8 Distribution of MP1 and Paxillin in cells spreading on 
collagen  
(A)Video of GFP-MP1 translocalization with RFP-Paxillin during HeLa JW 
cell spreading on collagen within 30 minutes, scale bar: 10 µm; (B) the 
selected time-lapse images of the cell spreading on collagen within 30 min. 
These images were taken at 0 min, 10min, 15min, 20 min, 30 min after the 
cells starting to spread. Scale bar: 10 µm. 
 
It is found from Andrew D Catling’s study that Paxillin was 
downregulated in MP1/p14-depleted DU145 cells (Park, Pullikuth et al. 2009). 
This correlation between the protein level of MP1/p14 and focal adhesion 
protein Paxillin suggests MP1/p14 might be essential for maintaining Paxillin 
level, either through the regulation on transcription or degradation. It is 
possible that MP1/p14 play a role in cell spreading by being involved in focal 
adhesion assembly/disassembly dynamics. Therefore, it is examined where 
will MP1 and Paxillin localize in well spread HeLa JW cells on collagen 
(Figure 2-6). On the near bottom layers of the cell, MP1-GFP and Paxillin-
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RFP are largely colocalized at the cell edge, especially at z stack 0.6um from 
the bottom, which is still within focal adhesion size (2-6 μm). Next it was 
tested whether the overexpression of MP1/p14 will affect Paxillin level or not. 
However, the expression level of Paxillin seems only correlated to total 
protein level rather than MP1 level in HeLa JW cell as shown in western blot 
result (Figure 2-7), in Lane 4 where there is no extra MP1 introduced into the 
cell, Paxillin level still remains high. However, our experiments cannot answer 
whether the lack of correlation is due to higher than threshold levels of MP1 in 
control cells already, or because MP1 has no affect on Paxillin’s level at all. 
Further knockdown experiments are required to prove this.  
Moreover, in order to examine the relationship between dynamics of 
MP1 and Paxillin, the distribution of MP1 and Paxillin during cell spreading 
on collagen was monitored. As recorded in Figure 2-8, GFP tagged MP1 are 
translocated outward with Paxillin-RFP at focal adhesions. However, this is 
not sufficiently conclusive either, as it could also be a consequent event as 
plasma membrane area increases. 








Figure 2-9 MP1 proteins traffic along microtubules 
 (A) Video of GFP-MP1 trafficking along microtubules after 100 ng/ml EGF 
stimulation, the video was taken within 30min of stimulation. Scale bar: 10 
µm; (B) the selected time-lapse images in 15 seconds within the 30 min. Red 
color labeled RFP-EB3 plasmid; Green color labeled GFP-MP1 plasmid, scale 










Figure 2-10 MP1 traffic together with Rab7 – late endosome marker 
 (A) Video of GFP-MP1 trafficking with mcherry-Rab7 after 100 ng/ml EGF 
stimulation, the video was taken within 30min of stimulation. Scale bar: 10 
µm; (B) the selected time-lapse images in 10 seconds within the 30 min, scale 




Figure 2-11 MP1 does not traffic along actin fibers. 
Video of GFP-MP1 trafficking in HeLa JW cells under 100 ng/ml EGF 
stimulation. The video was taken within 30 min of stimulation, with co-
staining of LifeAct, scale bar: 10 µm.  
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Under 100ng/ml EGF stimulation, real time live cell imaging of HeLa 
JW cells transfected with GFP-MP1 and cotransfected with RFP-EB3, 
mcherry -Rab7, RFP-LifeAct respectively showed that MAPK scaffold protein 
MP1/p14 moved together with late endosomes along microtubules, rather than 
along actin fibers (Figure 2-9 to Figure 2-11).  
Additionally, from our previous observation of the localization of MP1 
to focal adhesions during cell spreading (Figure 2-6 to Figure 2-8), a 
possibility was raised that MP1/p14 might also have a trafficking role in cell 
spreading by carrying focal adhesion proteins to the focal adhesion site, or 
even carrying late endosomes to the cell edge to contribute to the plasma 
membrane area increase during cell spreading.  
 
Figure 2-12 MP1-Rab7 trafficking under 100ng/ml EGF stimulation at 
different time points 
Red: mcherry-Rab7; Green: GFP-MP1. Scale bar: 5 µm. 
 
From distribution images of plasmid GFP-MP1 cotransfected with 
mcherry-Rab7 at 0, 5, 10, 15, 20, 25, 30 min under 100ng/ml EGF stimulation 
in HeLa JW cells, the area containing vesicles of MP1 and Rab7 is getting 
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smaller, and more focused to the cell nuclear area, indicating a pattern of MP1 
trafficking inward especially from 0min to 5min, 10min, 15min (Figure 2-12). 
The same pattern was observed in plasmid MP1-mcherry transfected HeLa JW 
cells. 
 
Figure 2-13 Western blot of EGF stimulated ERK activation in HeLa 
JW cells transfected with MP1 plasmid 
 
This trafficking mode seems to correlate temporally with EGF-
stimulated ERK activation profile. In response to 100 ng/ml EGF stimulus, 
there is a trend for MP1 moving inward from 0 min to 15 min, beyond that, the 
moving pattern is not obvious (Figure 2-12). Under the same high dose of 
EGF treatment, the activation of ERK is induced, and reaches its maximum at 
15 min, then the amount of active ERK reduces (Figure 2-13). It has been 
known from literatures that MP1 functions properly as a scaffold protein for 
ERK activation only when correctly positioned at perinuclear endosomes (Teis, 
Wunderlich et al. 2002), Therefore now it seems more specifically that MP1's 
effects on perinuclear endosome positioning correlate with its ability to 
activate ERK both spatially and temporally. 
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This raises a interesting question for further studies: How does scaffold 
protein MP1 regulate ERK activation spatially and assemble signaling 
competent modules under EGF stimulation? There are two possible 
mechanisms: (1) ERK are picked up at the near-membrane sites by MP1 then 
transported inward together with MP1, or (2) ERK just diffuse across the 
cytosol and get recruited to MP1-contained peri-nuclear endosomes. As a 
consequence, the loss of pERK in p14 knockdown cells might be because of 
deficiency of MP1-ERK trafficking inward and positioning properly to the 
perinuclear region, or because of the inability of MP1 to traffic inward to 
assemble ERK-MEK signaling complexes. The detail of this step is unknown 
due to the insufficient knowledge of how and when MP1/p14 dynamically 
assembles this signaling-competent complex. 
 
 
Figure 2-14 Localization of ERK after EGF stimulation for 10 min 
 (A) Flag-tagged ERK localization; (B) GFP-MP1 localization in cells 
cotransfected with ERK and MP1; (C) Flag-tagged ERK localization in cells 
cotransfected with ERK and MP1. Scale bar: 10 µm.     
 
To elucidate the detailed mechanisms of how MP1/p14 dynamically 
assembling the ERK signaling-competent complex, it is required to first make 
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it clear whether ERK localization changes after cotransfected with MP1 under 
EGF stimulation. Therefore, the ERK distribution with and without MP1 
cotransfection is examined. ERK distribution is obviously changed to 
concentrate more at cell edge, after cotransfected with MP1 when under EGF 
stimulation for 10 min (Figure 2-14). This observation favors more the first 
possibility of recruiting ERK at the near-membrane site. According to the 
change of ERK localization with MP1 overexpression, MP1 might also have 
active role in directing ERK to the cell membrane at early time points, then 
facilitate ERK activation through cell membrane targeted scaffold proteins, e.g. 
KSR. However, longer time scale immunofluorescence on ERK distribution 
with overexpressed MP1 level is required to confirm this.  
2.5 Conclusions and discussion 
Similarities of structure or surface accessibility are generally indicative 
of similar functions. In addition to enable us to elucidate structure-function 
relationships of MP1/p14 and dynein light chain LC7, it also provides a better 
understanding of MP1/p14 from interesting evolutionary perspectives. In vitro 
binding assay will be required to validate that MP1/p14 can traffic along 
microtubules. It would then be helpful to conduct experiments or analysis on 
checking the effect of mutation at the interaction site of MP1/p14 and 
microtubule. 
Colocalization and co-expression experiments of MP1-GFP and focal 
adhesion protein Paxillin reveal that MP1 and Paxillin might localize together 
at focal adhesion site to achieve ERK activation and focal adhesion assembly 
during cell spreading. However, the level of Paxillin seems not being affected 
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as expected in cells with overexpressed MP1 protein. Nonetheless, the results 
need to be repeated to get a final conclusion. Furthermore, a problem lies in 
monitoring MP1 distribution during cell spreading is that: continuous imaging 
of cells with time intervals of less than 2 seconds between two images is 
required to capture the fast dynamics of endosomal trafficking, while the 
successive laser applied will induce injuries to cells which cause them to stop 
spreading or spread abnormally. Therefore, novel methods of capturing the 
distribution dynamics of these proteins in cell spreading without side-effects 
are need to track the movement of intracellular proteins. 
MP1/p14 trafficking inward pattern in HeLa JW cells after EGF 
stimulation at different time points is observed through time lapse live cell 
imaging, and this dynamic spatial localization of MP1/p14 coincides with 
ERK temporal activation profile under EGF treatment. Moreover, the 
distribution of ERK is changed with cotransfection of MP1. All of these data 
indicates that the effect of MP1/p14 on perinuclear endosome positioning 
correlate with its ability to activate ERK both spatially and temporally. 
Nevertheless, longer time scale experiments on ERK distribution with 
overexpressed MP1 under EGF stimulus are required to understand the 
detailed mechanism of recruiting and assembling ERK signaling modules. 
2.6 Inspiration for further modeling work 
The imaging technique is implemented here to identify the possible 
role of MP1/p14 in cell spreading, through monitoring the movement and 
distribution of MP1/p14 and focal adhesion proteins during cell spreading. 
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Moreover, it is found that the scaffold protein MP1/p14 might have the role of 
coordinating the spatial distribution and activation of ERK in response to EGF.  
Our preliminary experiments, especially the ones on spatial and 
temporal coordination of MP1 trafficking and ERK activation upon EGF 
stimulus (Sections 2.4.3 and 2.4.4),  indicate that scaffold proteins could be 
important both spatially and temporally in regulating signaling dynamics and 
cell morphological change. However, more detailed information would be 
available if other scaffold proteins in MAPK pathway are involved to study 
the complex coordination of MAPK pathway by multiple regulators at 
systems-level.  
In mammalian cells, two scaffold proteins, Kinase Suppressor of Ras 
(KSR1) and MEK Partner 1 (MP1), are involved in the regulation of EGF-
induced ERK activation. As discussed in the next chapter, MP1/p14 mediated 
signaling on late endosomes is responsible for the chronic activation of ERK, 
which is suggested to be involved in several cellular processes including cell 
spreading and cytoskeletal trafficking. In contrast, KSR mediated signaling is 
known to promote transient ERK activation on plasma membrane. The fine 
coordination of scaffold proteins and other regulators in EGFR/ERK signaling 
could ultimately lead to various cellular responses upon internal and external 
perturbation, but the complete controlling mechanism and the interplay among 
these regulator proteins have not been understood yet.   
In the following chapters, in silico mathematical modeling will be used 
to conduct investigations on the co-regulation of KSR and MP1 in EGFR/ERK 
signal transduction (Chapter 3), and the long term effect of the pathway 
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output when cancer cells are given combination treatments targeting 



















Chapter 3 Simulation of EGFR-ERK 
Signaling Control by Scaffold Proteins 
 
Parts of this chapter are published in (Huang, Pan et al. 2011). Due to 
space limitation, Supplementary Files are not presented here; please refer to 




ERK activation is enhanced by the scaffolding proteins KSR and MP1, 
localized near the cell membrane and late endosome respectively, but little is 
known about their dynamic interplay.  We develop here a mathematical model 
with ordinary differential equations to describe the dynamic activation of 
EGFR-ERK signaling under a conventional pathway without scaffolds 
(EGFR-Ras-Raf-MEK-ERK), a KSR-scaffolded pathway, and an MP1-
scaffolded pathway, and their impacts were examined under the influence of 
the endosomal regulators, Cbl-CIN85 and Endophilin A1.  This new integrated 
model, validated against experimental results and computational constraints, 
shows that the change of ERK activation towards EGF (i.e. ligand sensitivity) 
can be shallow or steep, depending on these scaffold proteins and endosomal 
regulators.  The KSR-scaffolded pathway and the conventional pathway are 
sensitive to EGF stimulation and their combined effects on ERK activation are 
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synergistic.  When the KSR level is high, the sensitivity of this combined 
pathway remains low in the presence of low concentration of Cbl-CIN85 
while such sensitivity can be increased with increasing levels of Endophilin 
A1 if the amount of Cbl-CIN85 becomes high. However, reduced KSR level 
already presents high sensitivity that is independent of the levels of Endophilin 
A1. In contrast, the ERK activation by the MP1-scaffolded pathway is additive 
to that of KSR but it shows little ligand-sensitivity under high levels of EGF 
stimulation. Such inert sensitivity can, however, be partly reversed by 
increasing the level of Endophilin A1 while keeping the level of Cbl-CIN85 
low.  
These simulations constitute a multi-dimensional exploration of how 
EGF-dependent ERK activation is affected by scaffolds KSR and MP1 and 
their functions co-regulated by Cbl-CIN85 and Endophilin A1. Together, these 
results provide a detailed and quantitative demonstration of how regulators 
and scaffolds can collaborate to fine-tune the ligand-dependent sensitivity of 
ERK activation which could underlie the differences during normal 












3.2.1 Diverse outputs from ERK signaling 
The duration, magnitude and sub-cellular compartmentalization of 
ERK activation elicit different cellular outcomes leading to functional 
activation, proliferation, differentiation, migration, or survival (Ebisuya, 
Kondoh et al. 2005; Mor and Philips 2006). For instance, in HeLa JW cells, as 
has been shown in Chapter 2, the subcellular localization of ERK regulated 
by endosome scaffold proteins is critical for proper ERK activation and cell 
spreading. In PC12 cells (a cell line derived from a pheochromocytoma of the 
rat adrenal medulla), sustained ERK activation causes differentiation 
(Marshall 1998; York, Yao et al. 1998), strong ERK activation leads to 
differentiation in normal cells and survival in carcinoma cells, whereas weak 
ERK activation results in proliferation in normal cells and apoptosis in 
carcinoma cells (Murphy and Blenis 2006). These outcomes are collectively 
regulated by a number of regulators under different physiological conditions 
(Ebisuya, Kondoh et al. 2005; Murphy and Blenis 2006) and disease states, 
such as tumorigenesis (Dhillon, Hagan et al. 2007), cardiovascular disease 
(Budzyn, Marley et al. 2006; Shimokawa and Rashid 2007), and urinary 
bladder dysfunction (Peters, Schmidt et al. 2006).  
One important class of ERK regulators is scaffold proteins that 
compartmentalize and spatio-temporally control  ERK signaling to regulate 
signaling strength and duration, confer signaling specificity, diversify 
signaling kinetics, and prevent signaling activation by irrelevant stimuli 
(Morrison and Davis 2003; Kolch 2005; Shaw and Filbert 2009). Scaffold 
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proteins perform these tasks by assembling signaling components, localizing 
signaling molecules, coordinating positive and negative feedback, and 
insulating activated signaling molecules from inactivation. As has been shown 
from the analysis in Chapter 2, MP1/p14 plays important role in regulating 
ERK activation dynamics both temporally and spatially. On the other hand, 
Kinase Suppressor of Ras (KSR) is also involved in the regulation of EGF-
induced ERK signaling in PC12 (Muller, Cacace et al. 2000; Nada, Hondo et 
al. 2009) and other cells (Morrison and Davis 2003; Kolch 2005). KSR is a 
multi-domain protein that binds Raf-1, MEK, ERK, and several other proteins. 
In resting cells, it is sequestered in the cytosol by 14-3-3 proteins. In response 
to EGF stimulation, KSR is released from 14-3-3 and recruited to the plasma 
membrane to scaffold Raf-1, MEK1/2 and ERK1/2 and to subsequently 
facilitate Ras activation of the Raf-MEK-ERK module (Morrison and Davis 
2003; Kolch 2005).  
 
3.2.2 Coordinated actions of two scaffold protein – KSR 
and MP1 
Some important aspects and functional implications of the collective 
actions of these two scaffold proteins on ERK signaling have been studied. It 
has been suggested that sustained ERK activation may require coordinated 
control by KSR and the MP1-p14 complex to facilitate continued signaling 
from the plasma membrane to late endosomes (Pullikuth and Catling 2007), 
with KSR supporting the proliferative and transforming functions of ERK 
signaling and MP1 converting low MEK activity into sustained ERK 
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activation (Nguyen, Burack et al. 2002; Kolch 2005). Overexpression of both 
MP1 and KSR can lead to different responses, depending on the relative 
stoichiometry of the individual components (Vomastek, Schaeffer et al. 2004). 
For instance, overexpression of B-KSR in PC12 cells, a neuronal-specific 
isoform of KSR, switches EGF signaling from a brief proliferative signal to a 
sustained differentiation signal (Muller, Cacace et al. 2000). Because 
endosomes are immediately derived from the plasma membrane compartment, 
MP1-mediated signaling serves as an extension of KSR-mediated signaling at 
the cell membrane and maintains signaling at an adequate strength and 
duration, and in some cases with qualitatively different signaling kinetics, 
upon the removal of the activated receptors from the cell membrane (Morrison 
and Davis 2003). Furthermore, it enables the regulation of endosomal traffic 
and cellular proliferation during tissue homeostasis (Teis, Taub et al. 2006).  
KSR appears to play important roles in the regulation of adipogenesis 
(Kortum, Costanzo et al. 2005), neuronal differentiation and functioning 
(Muller, Cacace et al. 2000), Ras-mediated cancer formation, susceptibility 
toward rheumatoid arthritis (Lerdrup, Hommelgaard et al. 2006), and cellular 
sensitivity to anticancer agents (Stoeger and Cowan 2009). KSR also regulates 
the response of intestinal epithelial cells during inflammation and 
inflammatory bowel disease via activation of cell survival pathways 
(Kolesnick and Xing 2004; Yan, John et al. 2004). In comparison, the MP1-
p14 complex is required in prostate cancer cell migration (Park, Pullikuth et al. 
2009) via PAK1-dependent ERK activation during adhesion and cell 
spreading (Kirisits, Pils et al. 2007; Shtiegman, Kochupurakkal et al. 2007).  
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Despite such functional significance, the detailed dynamics and 
functional consequences of the coordinated actions of KSR and MP1 remain 
to be fully elucidated (Teis, Taub et al. 2006). These two scaffold proteins 
have opposite relationships with EGFR internalization. Note in the Figure 2-1, 
there is a feedback loop from ppERK to Epn through inhibition of ROCK 
phosphorylation, thus affecting EGFR internalization. This causes two 
different feedback mechanisms for KSR and MP1: Positive feedback for MP1, 
negative feedback loop for KSR. In the KSR pathway, activated ERK 
decreases the level of membrane bound EGFR, and in the MP1 pathway, 
activated ERK increases EGFR internalization. It is not known how one 
scaffold pathway will affect the dynamics of another scaffold pathway, so one 
purpose of our modeling will be to predict whether KSR and MP1 compete for 
sequestration of EFGR. Quantitative study of the effects by these scaffold 
proteins and other regulators on ERK signaling is useful for facilitating more 
comprehensive study and understanding whether they exert their roles in 
isolation or in concert during cell signaling and dynamics, disease 
manifestation and drug responses. To this end, a mathematical model of 
MAPK cascade with a generic scaffold protein has been developed and shown 
its capability in a quantitative analysis of the effects of scaffold–kinase 
complexes in regulating the specificity, efficiency, and amplitude of MAPK 
signal propagation (e.g., the levels of biphasic MAPK activation and the 
threshold of altered MAPK activation) (Levchenko, Bruck et al. 2000; 
Locasale, Shaw et al. 2007). This model can be combined with established 
mathematical models of the EGFR-ERK pathway (Kholodenko, Demin et al. 
1999; Brightman and Fell 2000; Schoeberl, Eichler-Jonsson et al. 2002; 
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Yamada, Taketomi et al. 2004; Sasagawa, Ozaki et al. 2005; Kiyatkin, 
Aksamitiene et al. 2006) and those coupled with such regulators as Sprouty 
(Yamada, Taketomi et al. 2004), Rap1 (Sasagawa, Ozaki et al. 2005), and 
MEKK1 (Li, Ung et al. 2009) to further examine the collective effects of these 
scaffold proteins and other regulators on ERK signaling.  
 
3.2.3 EGF gradient is important in physiological and 
non-physiological conditions. 
In normal and disease conditions, the circulating level of epidermal 
growth factor (EGF) is mostly not constant, either caused by fluctuation of 
growth factors or receptor binding. This concentration fluctuation might be 
essential physiologically for cell development and tissue repair (Yi, Lee et al. 
2008), since a number of previous studies have reported that the production 
and secretion variation of growth factors such as EGF during different 
developmental stages might exert a profound effect on tissue cell growth and 
differentiation (Tom-Moy and Barka 1981; Okamoto and Oka 1984; Kurachi 
and Oka 1985). During tumor cell invasion, elevated expression of EGF has 
been found to diffuse and generate a gradient of EGF receptor activation in 
adjacent cells, leading to an increase in tumor cell motility and invasiveness, 
thereby enhancing cancer cell metastasis (Price, Wilson et al. 1996; Xue, 
Wyckoff et al. 2006).  
3.2.4 EGFR internalization 
EGFR is activated through binding of EGF, followed by internalization 
into early endosomes from where it is either recycled to the plasma membrane 
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or sorted to late endosomes for degradation (Lai, Cameron et al. 1989; Lai, 
Cameron et al. 1989; Costa, Yan et al. 2003). Although endocytosis has 
traditionally been viewed simply as diminishing EGFR signaling (Wells, 
Welsh et al. 1990), evidence of increased tyrosine phosphorylation of 
endosomal EGFRs and their association of Shc and Grb2 indicates that 
endocytosis can temporally and spatially regulate the signaling cascades (Di 
Guglielmo, Baass et al. 1994; Sorkin, McClure et al. 2000; McPherson, Kay et 
al. 2001; Miaczynska, Pelkmans et al. 2004). An important step in initiating 
EGFR internalization is the binding of adaptor protein CIN85 to the ubiquitin 
ligase c-Cbl complex, which subsequently recruits activated EGFR on the 
plasma membrane (Soubeyran, Kowanetz et al. 2002; Dikic 2003). The 
complex then associates with other proteins such as endophilin A1, dynamin-2, 
synaptojanin and amphiphysin to drive clathrin assembly and EGFR 
endocytosis (Brodin, Low et al. 2000). However, in PC12 cells, active RhoA 
effector ROCK phosphorylates endophilin A1 and inhibits the recruitment of 
endophilin A1 to the EGFR–c-Cbl–CIN85 complex, thereby reducing the level 
of EGFR endocytosis (Kaneko, Maeda et al. 2005). These results raise the 
possibility that both Cbl and endophilin A1 could play an important role in 
coordinating Ras/ERK signaling. However, whether their effects are linked to 
scaffold functions of KSR or/and MP1 remains unknown.  
Based on our previous mathematical model of the EGFR-ERK 
pathway (Ung, Li et al. 2008; Li, Ung et al. 2009) and that of the MAPK 
cascade with generic scaffold proteins (Levchenko, Bruck et al. 2000; 
Locasale, Shaw et al. 2007), we here report a mathematical model of the 
EGFR-ERK pathway in PC12 cells that includes the two scaffold proteins 
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KSR and MP1 and we examine, for the first time, how the scaffolds could 
modulate the robustness and sensitivity of Ras/ERK under the influence of 
varied extracellular EGF concentrations and two intracellular regulators 
downstream of EGFR, the Cbl-CIN85 and Endophilin A1. In this integrated 
pathway model, ordinary differential equations were used to represent the 
time-dependent dynamic behavior of the concentration of proteins and other 
molecules and the kinetics of their interactions in the pathway. Our simulation 
model was validated by measuring the agreement with a number of 
experimental findings and previous simulation results for the effects of various 
perturbations (EGF, PP2A, MKP3, KSR, MP1, and p14) on ERK activities. 
Simulating the collective effect of KSR and MP1 on ERK activation revealed 
that KSR acts synergistically with the conventional EGFR-Ras-Raf-MEK-
ERK module to elicit acute ERK activation which is also sensitive to changes 
in the EGF concentrations. In contrast, MP1 appears to act in parallel 
(additively but not synergistically) with KSR for the chronic ERK activation 
which is not responsive to changes in the EGF concentrations unless by 
increasing level of Endophilin A1 while keeping the level of Cbl-CIN85 low. 
We found that the apparent difference in their ligand-sensitivity could be 
influenced not just by the scaffolds alone but most likely via their relative 
concentrations and interplay with other immediate regulators such as the Cbl-
CIN85 and Endophilin A1. All these results point to the importance of 
understanding the functional interplay between compartment-specific 
scaffolds and other immediate regulators in ensuring ligand-sensitivity of 
Ras/ERK signaling. Such responses could underlie the differences during 
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normal physiological and pathophysiological conditions as well as during drug 
treatments. 
3.3 Methods 
3.3.1  Model construction and components 
The pathway model used here is illustrated schematically in Figure 3-5. 
Two cascades were added to our earlier EGFR-ERK simulation model (Ung, 
Li et al. 2008; Li, Ung et al. 2009). These are the KSR and MP1 cascades 
based on the published models of the MAPK cascade with generic scaffold 
proteins (Levchenko, Bruck et al. 2000; Locasale, Shaw et al. 2007) as 
illustrated in Figures 3-6 and 3-7, respectively. These models were based on 
the following assumptions made by Levchenko et al (Levchenko, Bruck et al. 
2000) and supported by experimental data: (i) These scaffold proteins do not 
bind partially or fully activated kinases, based on the observation that MP1 has 
no effect on MEK-1 previously activated by B-Raf (Schaeffer, Catling et al. 
1998). (ii) Kinase activation by a scaffold protein is processive rather than 
distributive, based on two observations that MP1 increases B-raf activation of 
MEK-1 and that dual phosphorylation of MAPK at two sites (necessary for 
MAPK activation) take place simultaneously in the presence of MEF (a MEK-
enhancing factor from rabbit skeletal muscle) whereas phosphorylation at the 
second site is delayed by about 20 min in the absence of MEF (Scott, 
Haystead et al. 1995). (iii) The catalytic activity of a scaffold protein can be 
neglected in the model, as supported by the finding that the scaffolding 
function of KSR is independent of its kinase activity (Therrien, Michaud et al. 
1996; Michaud, Therrien et al. 1997). (iv) Kinases bind to scaffold proteins 
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independent of each other, as revealed by some experimental studies 
(Schaeffer, Catling et al. 1998; Roy, Laberge et al. 2002). (v) There is no 
inter-scaffold protein interaction, based on the fact that although p14 and MP1 
were suggested to be able to weakly self-associate in vitro (Wunderlich, Fialka 
et al. 2001), there has been no report to date of such homodimers detected in 
cellular systems. 
The constituent molecular interactions, their kinetic constants, and 
molecular concentrations are detailed in Supplementary Tables S1 and S2. The 
ordinary differential equations describing these interactions were derived 
based on mass action laws with interaction rate constants defined by the 
forward and reverse rate constants kf and kb or turnover kcats value used in the 
published models (Zhang, Chernoff et al. 1998; Kholodenko, Demin et al. 
1999; Schoeberl, Eichler-Jonsson et al. 2002; Yamada, Taketomi et al. 2004; 
Sasagawa, Ozaki et al. 2005; Kiyatkin, Aksamitiene et al. 2006) or reported 
from other literature. Our simulation model contains 541 equations and 
interactions and 412 distinct molecular species, characterized by 755 kinetic 
parameters (with 238 unique parameters) and 59 initial molecular 
concentrations. The model is built using KroneckerBio, a matlab toolbox 
developed in Tidor’s lab, MIT (Jared E. Toettcher 2011). A fourth order 
Runge-Kutta method with adaptive step-size control was used for integrating 
these equations. These ODEs were then solved using the Ode15 solver of 
Matlab. The reactions and initial conditions of our model are provided in the 




3.3.2 Collection and estimation of kinetic parameters 
The types of parameters used in our model are protein-protein 
interactions and catalytic activities. The published simulation studies have 
shown that most parameters are robust and insensitive to significantly alter the 
overall pathway behavior (Schoeberl, Eichler-Jonsson et al. 2002; Sasagawa, 
Ozaki et al. 2005). Apart from the use of the parameters of the published 
simulation models, additional parameters were obtained from the literature 
based on the widely used assumption that the parameters measured in vitro 
and in some cell lines are generally applicable in most cases. For those 
protein-protein interactions with unavailable parameters, their parameters were 
estimated from the known parameters of the relevant interacting domain 
profile pairs (Wojcik and Schachter 2001; Singhal and Resat 2007) or other 
interacting protein pairs of similar sequences.  
3.3.3 Model optimization, validation and parameter 
sensitivity analysis 
Mathematic models built at the systems level generally are expected to 
capture known behaviors or trends of specific systems qualitatively instead of 
reproducing exact quantitative trajectories in all systems. For instance, 
mathematic models of a biologic pathway based on parameters obtained 
experimentally from one cell type can produce slightly different behavior in 
another cell type. Differences in model behavior between cell types can be due 
to the differences in model topology and variation in kinetic parameters.  In 
the current study, we tentatively used a generic model of the scaffold proteins 
mediated EGFR/ERK signaling pathway to investigate the role of these two 
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scaffold proteins and endocytosis proteins in regulating ERK activation. The 
simulated results of levels of species with respect to time are up to empirical 
validation, i.e. validated against available experimental data. If the trend of 
dynamic behavior of a particular species behaves consistently with the 
experimental data, then the model is considered reasonable and can be used to 
analyze and make predictions on biological phenomena. However, if the 
simulation results do not agree or even are conflict with known experimental 
facts, the model has to be examined for possible errors, such as incorrect 
kinetic parameters. The cycle of optimization and validation are repeated until 
agreement between simulated results and known experimental trends were 
observed.  
The sensitivity of the simulation results with respect to the parameters 
were systematically analyzed to assess potential brittleness of the overall 
behavior to the parameter values.  We perform sensitivity analysis by 
computing the relative change of a system feature with respect to change in a 
parameter (Schlosser 1994). Here, the feature is the time integral of ppERK in 
1000 seconds (O), 
         
    
 
    (3-1) 
where x is the concentration of species ppERK, and t is the simulation 
time.  
The sensitivity (Sp) to a parameter p is: 











     (3-2) 
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The sensitivity of the time integral of ppERK in 1000 seconds with 
respect to all parameters and initial concentrations in the model was provided 
in Figure 3-1 (bar graph). Only a small subset of the parameters had any 
effect on the output.  The sensitive parameters were 5 reaction rates and 6 
initial protein concentrations, listed in Table 3-1.  These 11 parameters, 
constituting 4% of total parameters, all relate to ERK, MEK, or RasGDP 
reactions. We conclude that behavior of the model is strongly affected only by 
the downstream parameters that should have a strong effect, and the model 
shows no unexpected sensitivity or brittleness. 
 
 
Figure 3-1 Normalized parameter sensitivities toward the time integral 
of ppERK in 1000 seconds 
 
 
Table 3-1 A list of sensitive parameters in the pathway model 
Parameter 
index 
Name or reaction rate Value Sensitivity 
260 ERK1 0.2 0.115 
261 ERK2 0.2 0.115 
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266 MKP3 0.002 -0.0508 
53 kd33  
(ppMEK2 dephosphorylation) 
0.058 -0.0369 
273 PP2A 0.02 -0.0366 
283 RasGDP 0.15 0.0348 




51 k32  
(ppMEK2 dephosphorylation) 
14.3 -0.0327 




3.3.4 Robustness analysis 
In order to measure the robustness of the model, all the parameters 
were allowed to vary randomly within a 50% range of the current value. 1000 
such random models were sampled, and the changes of integrated ppERK in 
the first 1000 seconds were measured.  
First of all, the ERK activation profile from 100 of these random 
models were presented in Figure 3-2, we can find that variation do not alter 
the agreement of our model with experiments. Although the individual 
maximum amplitude of ERK activation varies, the activation kinetics of ERK 
in each model match well temporally: ERK activation peaks within 10 min, 




Figure 3-2 ERK activation profiles from 100 random models.   
The thick red line denotes the profile of the original model. 
 
Furthermore, the histogram of the distribution of the integrated ppERK 
of these 1000 random models is shown (Figure 3-3). As statistically evaluated 
in Figure 3-4, 80% of these models produce ppERK amount in 20% range of 
original model output, which presents the robustness of our model. 
 






Figure 3-4 The percent of perturbed models that have output levels 
(integrated ppERK) within a given percent range of the original output 
 
3.3.5 Ligand-sensitivity analysis 
To quantify how ERK activation in these two different compartments 
responds to changing EGF concentrations, we used the total amount of active 





O ( , , ) ( )t x u x t dt      (3-3) 
where x is the species active ERK, u is the EGF stimulus, and t is the 
simulation time.  
 The full derivatives of the objective function 
1O ( , , )t x u with respect to 










    (3-4)
 
Similarly, the ligand sensitivity on endocytosized EGFR is quantified 
by calculating the derivatives of the total amount of endocytosized EGFR 
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(denoted as “EGF-pEGFR-2-Grb2-SOS_e” in reactions 158 and 159, 
Supplementary Table S1) in the first 1000 seconds toward EGF variation. 
So the objective function is the total amount of endocytosized EGFR 





O ( , , ) ( )t y u y t dt      (3-5) 
where y is the endotytosized EGFR, u is the EGF stimulus, and t is the 
simulation time. 
The full derivative of the objective function           with respect to 










    (3-6) 
Since c-Cbl-CIN85 and Endophilin A1 will affect the duration of ERK 
activation through regulation of EGFR degradation and turnover, we want to 
know whether c-Cbl-mediated endocytosis pathway will affect the ERK 
activation sensitivities. We also investigated to what extent the ERK activation 
sensitivities are influenced in the two different compartments toward variation 
of EGF stimulation. 
Then we calculated the effect of c-Cbl-CIN85 and Endophilin A1 
concentration on the ERK production sensitivity from the two sub-pathways 
(membrane and endosomal) toward EGF concentration, individually and in a 









     (3-7) 
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Here, C1 is the initial concentration of c-Cbl-CIN85, and C2 is the 
initial concentration of Endophilin A1. 
3.3.6 Effect of scaffold concentrations on ligand-
sensitivity analysis 
To evaluate the effect of scaffold protein concentrations on Cbl and 
Endophilin A1-mediated compartment-specific response toward EGF variation, 
we set the level of KSR and MP1 to the ones optimal for signaling (which is 
the concentration for the maximum total amount of active ERK produced in 
the first 1000 seconds across 0 – 1.0 µM scaffold concentration, Figure 3-8B 















3.4 Results and Discussion 
3.4.1 Constructing a new mathematical model of EGFR-
ERK signaling with key scaffolds and regulators 
 
Figure 3-5       Pathway model used in this study.  
The detailed biochemical model of scaffolding action of KSR and MP1 in the 
dashed rectangular boxes are shown in Figure 3-6 and 3-7, respectively. 
Molecules highlighted in blue, green and yellow boxes represent the separate 
modules of Ras/ERK signaling operating from the conventional mode (no-
scaffolds; membrane), KSR-supported mode (membrane) and MP1-supported 
mode (late endosomes) , respectively. 
 
To examine the impacts by the two compartment-specific scaffolds 
KSR and MP1 on Ras/ERK activity under the influence of Cbl and Endophilin 
A1 and varying EGF concentrations, we have constructed a new mathematical 
model by integrating these molecular species as depicted in Figure 3-5. It 
takes into consideration the biochemical model of scaffolding actions by KSR 
and MP1 (Figures 3-6 and 3-7, respectively), which are based on previous 
models of the MAPK cascade with generic scaffold proteins (Levchenko, 
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Bruck et al. 2000; Locasale, Shaw et al. 2007). Detailed molecular interactions 
and the corresponding kinetic data were obtained from the published 
simulation models and further literature, summarized in Supplementary Table 
S1 (Huang, Pan et al. 2011). 
 
 
Figure 3-6 The detailed biochemical model of scaffolding action of 
KSR.  
Please refer to “Methods” for the considerations and assumptions used and 
Supplementary Table S1 for detailed description on their kinetics parameters. 





Figure 3-7 The detailed biochemical model of scaffolding action of 
MP1.  
 
Please refer to “Methods” for the considerations and assumptions used and 
Supplementary Table S1 for detailed description on their kinetics parameters. 
“P” denotes protein phosphorylation. 
 
Toward validating the model, we examined whether the results are 
consistent with experimental observations. The results in Supplementary 
Figures S3-1 and S3-2 show that at 100 ng/ml EGF, the simulated ERK 
activation peaks at ~5 minutes and decays within 50 minutes. This is 
consistent with the observation that treatment of 100 ng/ml EGF in PC12 cells 
transiently activates ERK, which peaks within 5 minutes and thereafter it 
decays within 30-60 minutes (Traverse, Seedorf et al. 1994; Sasagawa, Ozaki 
et al. 2005). Upon EGF stimulation, SOS is recruited to the plasma membrane 
where it activates Ras, switching inactive GDP-bound Ras into active GTP-
bound form, and recruits the Raf kinase to the plasma membrane, initiating the 
signaling cascades. Similarly, our simulation shows that the amount of active 
RasGTP peaks at ~2.5 minutes and quickly it decays within 20 minutes, 
consistent with the observation that active RasGTP levels in EGF-treated 
PC12 cells increase dramatically within 5 minutes and decay steeply within 10 
minutes (Sasagawa, Ozaki et al. 2005).  
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3.4.2 Simulation models of KSR and MP1/p14-mediated 
pathways 
Recent studies have identified the double effects of MAPK scaffold 
proteins KSR and MP1 on ERK activation, with the hallmark of either 
promoting or inhibiting the signals depending on their local concentrations. 
The promoting effect is due to the ability of the scaffolds to recruit the 
proteins to a limited number of locations where each has high concentration of 
partner proteins. However, an excessive number of locations where each has 
low concentration would sequester the individual protein partners from 
reaching each other (Burack and Shaw 2000; Morrison 2001; Yao and Seger 
2009). The kinetics of KSR-mediated signaling in this model was validated by 
evaluating the effect of altered KSR concentration on ERK activation. When 
KSR1 was experimentally re-introduced into KSR1
 -/-
 mouse embryonic 
fibroblasts, it demonstrates a biphasic effect on ERK signaling, such that 
signaling is increased in a concentration-dependent manner when KSR 
concentration is increased to up to 14 fold of wild-type levels (Kortum and 
Lewis 2004).  
However, further increase of KSR concentration leads to decreased 
ERK signaling (Kortum and Lewis 2004). Such distinct biphasic effect of 
KSR is demonstrated in our simulation results (Figure 3-8A and 3-8B) such 
that at low concentrations, KSR has a positive effect on ERK activation; while 




Figure 3-8 The biphasic effect of KSR concentration on ERK 
activation.  
 
 (A) Percentage of active ERK was plotted over the period indicated by 
varying the concentrations of KSR from 0 to 2 µM. (B)  Existence of an 
optimal scaffold concentration of KSR (0.3-0.5 µM) by plotting the time 
integral of ppERK/ERK in the first 1000 seconds and KSR’s initial 
concentrations. 
 
Similarly, the kinetics of MP1-mediated signaling was also validated 
by evaluating the effect of altered concentrations of MP1 adaptor protein p14 
on ERK activation. As shown in Figure 3-9, p14 “knockout” only affects the 
later phase of activated ERK dynamics, resulting in a decrease in the duration 
of ERK activation. This result is consistent with the observation that the MP1-
p14 complex is not required for initial signaling near the plasma membrane 
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but is necessary for the activation at endosomes 10-30 min following EGF 
treatment in HeLa cells (Teis, Wunderlich et al. 2002). This illustrates the 
intricate mechanism that exists in a given cell allowing the MAPK pathway to 
be activated with different kinetics through localized scaffold proteins, an 
essential feature of compartmentalized signaling. 
 
 
Figure 3-9 The profile of active ERK before and after p14 knockout.  
The amount of active ERK produced in the later phase (> 600 seconds) is 
reduced. 
 
Moreover, the scaffold-specific biphasic property of MP1 can be 
observed through the simulated plot here, as consistent with a reported result 
that higher level of MP1 will lead to inhibition of signaling (Figure 3-10) 
(Schaeffer, Catling et al. 1998). The findings that the expression level of 
scaffold protein in wildtype cells is sub-optimal for signaling, may provide 
regulatory flexibility as tuning scaffold protein expression up or down directly 




Figure 3-10 The biphasic effect of MP1 concentration on ERK 
activation. 
 (A) Percentage of active ERK was plotted over the period indicated by 
varying the concentrations of MP1 from 0 to 2 µM. (B) Existence of an 
optimal scaffold concentration of MP1 (0.1 µM) by plotting the time integral 




We also studied the biphasic behavior as a function of both KSR and 
MP1 concentrations (Figure 3-11). As expected, we note that the shapes of the 
biphasic curve of KSR and MP1 are different, with the KSR showing slower 




Figure 3-11 A three-dimensional plot of time integral of ppERK with 
respect to KSR and MP1 level variation. 
 
This could reflect the difference on number of member proteins each 
scaffold protein tethers. As a 3-member scaffold protein, KSR is less efficient 
compared to MP1 in forming signaling competent complexes, i.e. one KSR 
with 3 member proteins on it, so it could be slower for increasing the ppERK 
amount as KSR concentration increases; however, once it reaches its optimal, 
it is more efficient in losing this competency in signaling (because 1/3 chance 
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will be enough to lose it), so it could be faster for decreasing the ppERK 
amount as KSR concentration decreases. Suppose there is an abundance of the 
3 member kinases, in that case, many scaffolded complexes would start to 
form and because of the speed limitation from the kinase binding to scaffold 
proteins, it would take relatively longer for all 3 kinases to bind to one 
scaffold protein to form one complete signaling competent complex. When the 
scaffold protein is in excess, it will lead to separation of kinases into 
nonfunctional complexes and inhibit signaling. Because of the signaling 
competent complex requires 3 kinases binding to one scaffold protein 
simultaneously, a significant decrease in signaling can occur when the scaffold 
concentration is greater than optimal. If instead the scaffold protein is a 2-
member scaffold, 2 kinases binding to one scaffold protein would be enough 
to form a complete signaling-competent molecule, and when the scaffold 
protein is in excess, it would be relatively more difficult to lose the signaling 
capability.  
To further validate how the current model operates in the presence of 
other signaling nodes, we evaluated the significance of phosphatases PP2A 
and MKP3 on ERK activation. As a result, variation of PP2A at low 
concentrations from 0.005 to 0.01 µM showed little effect on the maximal 
ERK activation but they reduced the rate of its decay. Similarly, at lower 
levels, variation of MKP3 levels from 0.0005 to 0.001 µM had little effect on 
the maximal ERK activation but they also reduced the rate of its decay 
(Mayawala, Gelmi et al. 2004). In contrast, at higher levels of PP2A and 
MKP3, both the maximal amount and duration of ERK activation had 
decreased. Taken together, our newly refined model recapitulates core 
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signaling dynamics observed in the presence of KSR and MP1 and is ready to 
interrogate how they would function independently or collectively in various 
EGF regimes as further detailed below. 
3.4.3  Collective effects of KSR and MP1 on ERK 
activation 
Next, the effect of KSR and MP1 on ERK activation was simulated 
under the condition without these scaffolds (conventional) or with their 
presence, either separately or together. The results show that both KSR and 
MP1 increased the level of acute ERK activation within 2000 s, and with only 
the MP1 contribution, the signal was maintained for more than 7200 seconds 
(Figure 3-12A). This simulation result is consistent with the experimental 
indication that sustained ERK activation may arise from collective action of 
KSR and MP1 (Pullikuth and Catling 2007). The slight difference between the 
MP1-mediated ERK activation profile (Figure 3-12A) and the KSR-knockout 
ERK activation profile (Figure 3-12B) is mainly due to the contribution from 





Figure 3-12 The collective effect of KSR and MP1 on ERK activation. 
 (A) Overall signaling and contribution from individual modules. (B)  
Signaling profile under knockout conditions. 
 
However, under the MP1-knockout condition, i.e. MP1 concentration 
is 0, there is a moderate reduction in the level of ERK activation at short times 
of up to 2000 s, but it completely eliminated the sustained activation of ERK 
at times beyond 3000 s. In strong contrast, the KSR-knockout significantly 
reduced the level of ERK activation at short times of up to 2000 s, but ERK 
activation was not reduced at times beyond 3000 s (Figure 3-12B). This is 
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also consistent with the experimental indication that KSR supports the 
proliferative and transforming functions of ERK, and MP1 converts low MEK 
activity into sustained ERK activation (Nguyen, Burack et al. 2002; Kolch 
2005). While the results strongly indicate that both scaffolds contribute to the 
majority, if not all of ERK activation in the current model, it remains unclear 
whether they exert their effects in parallel (additively) or in synergy or 
whether both pathways are subjected to fluctuations of EGF concentrations. 
To examine this, we went on to simulate ERK dynamics by KSR and/or MP1, 
separately or together when subjected to varying concentrations of EGF as 
described below. 
Quantitatively, our simulations suggested that MP1 knockout reduces 
the peak amplitude of ERK activation by 25%, which is consistent with the 
observed 30% reduction of ERK activation by the loss of function of p18 that 
excludes the p14-MP1 complex from late endosomes (Nada, Hondo et al. 
2009). Our simulations also predicted that KSR knockout would reduce the 
peak amplitude of ERK activation by 50%, which is consistent with the 
observation that ERK activation in response to multiple stimuli was attenuated 
but not abolished in the KSR
–/–
 mouse embryo fibroblasts (Nguyen, Burack et 
al. 2002). As strong and transient ERK activation is required for the 
proliferation of PC12 cells (Murphy and Blenis 2006), the significantly 
reduced peak/amplitude in the KSR knockout is expected to significantly limit 
the proliferation processes. This is consistent with the experimental finding 
that loss of KSR1 expression attenuated ERK signaling and abolished the 
capability of oncogenic Ras to induce skin cancer in KSR
–/–
 mice (Lozano, 
Xing et al. 2003). Moreover, our simulation suggested that double knockout of 
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KSR and MP1 significantly reduced the strength and duration of ERK 
activation with the peak being reduced by 8-fold.  
3.4.4 Synergistic ERK activation by the conventional 
module and KSR-mediated module 
Experimental (Giurisato, Lin et al. 2009; Lin, Harding et al. 2009) and 
computational (Locasale, Shaw et al. 2007) studies have shown that, due to its 
scaffolding activities, KSR enhances the efficiency of ERK activation without 
altering the fundamental system outputs, i.e. the incoming signals are 
amplified or attenuated in different biological contexts and at different KSR 
concentrations. Underlying this fundamental consistency is a complex 
interplay between conventional pathway and pathways mediated by scaffolds. 
Based on models of the MAPK cascade with generic scaffold proteins 
(Levchenko, Bruck et al. 2000; Locasale, Shaw et al. 2007), shown in Figure 
3-6, KSR at cell membranes releases activated signaling molecules and 
competes with the conventional unscaffolded pathway for inactive signaling 
molecules. The former action enhances and the latter action reduces the 
capability of the conventional pathway for ERK activation. If the former 
action outweighs the latter, then KSR is expected to enhance ERK activation 
not only by its own signaling but also by synergistically increasing the 
signaling of the conventional unscaffolded pathway. The contribution of the 
conventional pathway with and without KSR (Figures 3-13A) and the KSR-
mediated pathway with and without the conventional route of ERK activation 
(Figure 3-13B) were compared. The results show that the level of ERK 
activation arising from signaling via the conventional pathway in the presence 
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of KSR is significantly increased with respect to that without KSR (Figure 3-
13A) whereas the level of ERK activation arising from signaling via the KSR-
mediated pathway in the presence of the conventional one is slightly decreased 
when compared to that without the conventional pathway (Figure 3-13B). 
Consistently, Figure 3-13C shows the synergistic effect of the conventional 
and KSR-mediated pathways on ERK activation. Therefore, our simulation 
study suggested that the signal-enhancing action of KSR on the conventional 
pathway significantly outweighs its signal-reducing action on the conventional 
module, leading to a significantly stronger combined signaling from the two 
membrane modules than the simple sum of each individual component. This 
synergistic effect may enable sizable ERK activation at moderate or 
suboptimal (which is below the concentration for the maximum total amount 
of active ERK produced in the first 1000 seconds across 0 – 1.0 µM scaffold 
concentration, Figure 3-8B and 3-10B) levels of KSR in many cells (Stoeger 





Figure 3-13 The synergistic effect of the two membrane associated 
signaling components. 
The conventional EGFR–Ras–Raf–MEK–ERK signaling module (Convent) 
and the KSR-mediated module (KSR) on ERK activation.  
 
3.4.5 Distinct signaling dynamics of the membrane and 
late endosome components in response to varying EGF levels 
Since under various physiological conditions, concentrations of growth 
factors are more likely to change and present in a gradient instead of being 
constant, we set out to examine whether there exists any significant 
perturbations in the signaling dynamics of the membrane and late endosomal 
components in response to varying EGF levels. Figure 3-14 shows the 
contribution of the membrane (conventional and KSR-mediated pathways) and 
late endosome (MP1-mediated pathway) components, toward ERK activation, 
for EGF concentrations ranging from 25 ng/ml to 100 ng/ml. Interestingly, the 
signaling via the late endosomal component is insensitive to varying the EGF 
concentrations under this condition. In contrast, signaling through the two 
membrane components is substantially altered by varying EGF doses, 
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specifically when EGF is reduced from 40ng/ml to 25ng/ml. Figure S3-5 
further shows the relative sensitivity of these two sub-pathways at high EGF 
dose – the sensitivity of membrane subpathway (conventional and KSR-
mediated one) is almost 4 times the sensitivity of endosomal subpathway. 
These results are consistent with the prediction using principle component 
analysis that receptor internalization and endosomal signaling are important 
features regulating signal output at lower EGF doses (Liu, Swihart et al. 2005). 
 
Figure 3-14 Contribution of individual modules to the overall ERK 
signaling at various EGF concentrations. 
The contribution of the two membrane and one endosome components, the 
conventional EGFR–Ras–Raf–MEK–ERK signaling module (Convent), the 
KSR-mediated module (KSR), and the MP1 module (MP1), on ERK 
activation at various EGF concentrations: (A) 100 ng/ml, (B) 60 ng/ml, (C) 40 




3.4.6 The compartment-specific sensitivity toward EGF 
variation is co-regulated by endocytosis proteins and scaffold 
proteins 
Through ligand-induced receptor activation, any changes in the EGF 
concentrations could lead to altered levels of activated EGFR on the cell 
surface, thus affecting its downstream signaling via both the membrane 
components (the conventional and KSR-mediated pathway) and the late 
endosomal component (MP1-mediated pathway). We therefore hypothesize 
that the apparent difference in their ligand-sensitivity could be influenced not 
just by the scaffolds alone but most likely via their relative concentrations and 
interplay with other immediate regulators such as the Cbl-CIN85 and 
Endophilin A1. To this end, we conducted further simulations by varying 
concentrations of Cbl-CIN85 complex and Endophilin A1 and tested their 
impacts on the ligand sensitivity mediated by the membrane (conventional 
plus KSR)  or the endosomal module (MP1) under the following 4 conditions: 
(1) when both scaffolds are present in suboptimal “low” levels [KSR = 0.02 
µM, MP1 = 0.02 µM] (Figure 3-15), (2) when both scaffolds are present in 
optimally “high” concentrations as determined earlier [KSR:  0.3 µM, MP1 
0.3 µM] (Figure 3-16), (3) when KSR is present at “high” level [0.3 µM] and 
MP1 at “low” level [0.02 µM], and (4) when MP1 is present at “high” level 
[0.3 µM] and KSR is at “low” level [0.02 µM]. Results of sensitivity analyses 
in Figure S3-5 show that the MP1-scaffolded module bears little sensitivity to 
EGF dose changes under condition (1) when both scaffolds are present in 




Figure 3-15 Sensitivities of individual subpathways when both scaffold 
proteins are at low level. 
Differential sensitivity of ppERK from (A) membrane and (B) endosomal 





Figure 3-16 Sensitivities of individual subpathways when both scaffold 
proteins are at optimal level. 
When scaffold proteins KSR and MP1 are highly expressed – optimal for 
signaling, differential sensitivity of ppERK from (A) membrane and (B) 
endosomal subpathways for EGF under various Cbl-CIN85 and Endophilin 
A1 concentrations. For clarity purposes, the levels of sensitivities are denoted 
by colors in the scale bars. 
 
The KSR-scaffolded pathway and the conventional pathway are 
sensitive to EGF stimulation and their combined effects on ERK activation are 
synergistic.  When the KSR level is high, the sensitivity of this combined 
pathway remains low in the presence of low concentration of Cbl-CIN85 
while such sensitivity can be increased with increasing levels of Endophilin 
A1 if the amount of Cbl-CIN85 becomes high (Figure 3-17, Panels A and C). 
However, reduced KSR level already presents high sensitivity that is 
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independent of the levels of Endophilin A1 (Figure 3-17, panels B and D). In 
contrast, the ERK activation by MP1-scaffolded pathway is additive to that of 
KSR but it shows little ligand-sensitivity under high levels of EGF stimulation. 
Such inert sensitivity can, however, be reversed in part by increasing the level 
of Endophilin A1 while keeping the level of Cbl-CIN85 low (Figure 3-17, 
Panels E, F, G, H) or by increasing the level of Cbl-CIN85 while keeping the 





Figure 3-17 Detailed analysis of sensitivities of ppERK from individual 
subpathways mediated by scaffold proteins under various situations. 
Detailed analysis on the sensitivities of activated ERK mediated by scaffold 
proteins KSR and MP1 and modulators Cbl-CIN85 and Endophilin A1 under 
various situations. Sensitivities of first and third panel (A, B, C, D, I, J, K, L) 
KSR-mediated and conventional; second and fourth panel (E, F, G, H, M, N, 
O, P) MP1-mediated subpathways toward EGF variation regulated by (A - H) 
Endophilin A1 concentration variation when Cbl-CIN85 is low (0.0001 µM) 
or high (0.8 µM); (I - P) Cbl-CIN85 concentration variation when Endophilin 
A1 is low or high at four conditions: (A, E, I, M) when both scaffolds are 
present in suboptimal “low” levels [KSR = 0.02 µM, MP1 = 0.02 µM]; (B, F, 
J, N) when both scaffolds are present in optimally “high” concentrations as 
determined earlier  [KSR:  0.3 µM, MP1 0.3 µM]; (C, G, K, O) when KSR is 
present at “high” level [0.3 µM] and MP1 at “low” level [0.02 µM]; (D, H, L, 
P) when MP1 is present at “high” level [0.3 µM] and KSR is at “low” level 
[0.02 µM].  
 
Thus, this current study extends the observations of others (Schoeberl, 
Eichler-Jonsson et al. 2002), thereby suggesting that the endocytosis process 
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plays a prominent role in regulating signal output sensitivity toward different 
EGF dosages.  
Since influences of Cbl-CIN85 and Endophilin A1 enter the pathway 
by promoting the endocytosis of activated EGF receptors and trafficking them 
to late endosomes, we went on to analyze the concomitant modulation of 
receptor/ligand endocytosis along with the ERK activity dynamics (Figure 3-
18). Our analyses show that, when levels of scaffold proteins KSR or MP1 are 
either high or low, the sensitivity of endocytosed EGFR increases with 
increasing levels of Endophilin A1 if Cbl-CIN85 was present at high levels. 
However, when the Cbl-CIN85 level is low, this sensitivity will start with a 
dramatic decrease till a rather stable low in the situations when KSR is at 
optimal concentration. However, this dramatic decreasing effect will be 
abolished when both scaffold proteins are at suboptimal concentrations or only 
MP1 is at high level, but rather have mild sensitivity change of endocytosed 
EGFR toward EGF variation.  This supports that scaffold proteins regulate and 
control the downstream active ERK sensitivity response toward ligand 
variation. 
Comparison between these two sensitivities (sensitivities of 
endocytosed EGFR and endosomal ppERK) reveals that the downstream 
ppERK sensitivity change seems to be kept lower compared to upstream 
endocytosed EGFR. Although at high Cbl-CIN85 level, sensitivity of 
endocytosed EGFR is high, the sensitivity of endosomal ppERK is kept low, 
which might suggest the important role of endosomal scaffold protein MP1 in 
dowstream ppERK robustness maintenance (Figure 3-18A to D). At low Cbl-
CIN85 level, the two general trends of sensitivity profiles resemble each other 
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when KSR are at low level; while when KSR is at optimal level, the sensitivity 
of endosomal ppERK is quite stable even though the sensitivity of 
endocytosed EGFR change significantly, suggesting that KSR might bear less 
affection on ligand sensitivity of ppERK from the endosomal subpathway. 
Together with the result that MP1 contributes to the robustness maintenance of 
downstream endosomal ppERK, the analysis on EGFR endocytosis seems to 
give us a hint on the role of the two scaffold proteins in ligand sensitivity 
regulation. 
All these results define the unique response of ERK activation to EGF 
that depends closely on the relative levels of not just the key scaffold proteins 
KSR and MP1, but also the influence by the endosomal regulators, Cbl-CIN85 
and Endophilin A1. These analyses further support the multi-dimensional 
regulation of ligand sensitivity by the accessory proteins including the scaffold 
proteins and endocytosis regulators. 
 
 
Figure 3-18 Detailed analysis of the sensitivities of endocytosed EGFR 
mediated by scaffold proteins under various situations. 
Sensitivities of endocytosed EGFR  toward EGF variation (A to D) regulated 
by Endophilin A1 concentration variation when Cbl-CIN85 is low (0.0001 µM) 
or high (0.8 µM); (E to H) Cbl-CIN85 concentration variation when 
Endophilin A1 is low (0.0001 µM) or high (0.8 µM): (A, E) when both 
scaffolds are present in suboptimal “low” levels [KSR = 0.02 µM, MP1 = 0.02 
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µM]; (B, F) when both scaffolds are present in optimally “high” 
concentrations as determined earlier  [KSR:  0.3 µM, MP1 0.3 µM]; (C, G) 
when KSR is present at “high” level [0.3 µM] and MP1 at “low” level [0.02 
µM]; (D, H) when MP1 is present at “high” level [0.3 µM] and KSR is at “low” 
level [0.02 µM]. 
3.4.7 SHP2 also influences the ligand sensitivities of 
ERK activation 
There is plenty of evidence supporting the positive role of SHP2 on 
ERK activation in MAPK pathway and its association with receptor 
endocytosis, which is also highly cell type and stimulator dependent. But little 
is known about how SHP2, as an important upstream signaling component, 
contributes to the multi-dimensional ligand sensitivity regulation.  
In order to further examine this, as referred to several papers, we 
incorporated the double negative feedback loop (SHP2 ─┤ phosphorylated 
EGFR-RasGAP ─┤ RasGTP; where ─┤ denotes inhibition) to capture the 
main positive role of SHP2 on ERK activation (Agazie and Hayman 2003; 
Neel, Gu et al. 2003; Mohi and Neel 2007). Our initial analyses implies that 
under the positive influence of SHP2, the sensitivities of ERK activation by 
the scaffolds and Cbl-Endophilin coregulation undergoes dramatic fluctuations.  
However, this requires more detailed simulation of the phosphorylation 
and dephosphorylation sites on EGFR by different kinases and phosphorytases, 
which actually need some major modification on the current EGFR all-or-none 
phosphorylated models. As a consequence, although our preliminary studies 
cannot fully address this question now, this can still help us on understanding 
those interesting novel experimental results (Araki, Nawa et al. 2003; Lazzara, 
Lane et al. 2010), as the obvious more complex sensitivity fluctuation profile 
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Figure 3-19 Hypothesized model: the distinct dynamics of ERK 
activation. 
 
EGF-induced downstream ERK activation are collectively regulated at two 
different compartments: near the plasma membrane (the conventional EGFR-
Ras-Raf-MEK-ERK module and KSR-mediated signaling), and at late 
endosomes (MP1-mediated signaling through endocytosed EGFR by Cbl-
CIN85 complex). In this model, (A) when scaffold proteins are in low level, 
the two subpathways show distinctive sensitivities toward growth factor 
83 
 
stimulation, which could be influenced differently by c-Cbl-CIN85, but less 
slightly influenced by Endophilin A1; (B) however, when scaffold proteins are 
in high level, both sensitivities of the two subpathways are regulated by these 
two proteins. 
3.5 Conclusions and discussion 
Sensitivities of pathways reflect the ability of a system to react against 
varying environments, and robustness against intracellular as well as 
extracellular perturbations. Our newly integrative simulation model, optimized 
and validated against a number of experimental and published simulation 
results, reveals the collective effects of KSR and MP1 on ERK activation and 
ligand sensitivity, depending on the relative levels of these scaffold proteins 
and also the immediate regulators.  
While being able to predict variation of ERK activation induced by 
KSR and MP1 knockout, our simulation also reveals that KSR synergistically 
enhances signaling via the conventional EGFR-Ras-Raf-MEK-ERK pathway. 
However, the effect from MP1 appears to be additive to that of the KSR-
mediated pathway and unlike KSR, it is insensitive towards EGF variation 
across the range of 25–100 ng/ml unless the level of EGF is present at much 
lower level and there is an reciprocal change in the levels of Endophilin A1 
and Cbl-CIN85. Under such conditions, the inert response can be reversed by 
increasing levels of Endophilin A1 while keeping the levels of Cbl-CIN85 low 
(Figure 3-17, Panels E, F, G, H) or by increasing the level of Cbl-CIN85 
while keeping the level of Endophilin A1 low (Figure 3-17, Panels M, N, O, 
P). Further analyses on the ligand sensitivity of endocytosed EGFR showed 
that high levels of KSR exerts a more profound effect on the response whereas 
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MP1 helps maintain the robustness of the endosomal ERK activation instead 
of the endocytosed EGFR. 
In summary, using scaffold-mediated signaling as an example, we have 
demonstrated that various components in the EGF signaling pathway have 
distinct contributions (i.e. scaffolds or regulators) and they respond and act in 
concert to execute the final signal output as a function of varying EGF 
concentrations and times after stimulation (Figure 3-19).  
3.6 Outlook on experimental validation 
This chapter is focused on regulation of EGF-stimulated ERK 
activation through scaffold proteins and endocytosis proteins. More 
specifically, it analyzed how regulator proteins interplay with each other and 
coordinate the basic motifs of intracellular signalling networks. In this section, 
some future experiments are proposed to test our model predictions. 
Quantitative measurements of the concentration effect of KSR or MP1 
on the MAPK pathway outputs can be performed. Besides, cell morphology or 
long distance delivery in ksr1 or mp1 mutant PC12 cells expressing increasing 
levels of KSR1 or MP1 can be examined. Such experiments can help us link 
the level of scaffold proteins and the MAPK output in this pathway to specific 
biological processes. Together with the immunofluorescent staining and 
bioimaging technique, we can dissect the ERK phosphorylation by different 
activation pools confined by scaffold proteins. This will help us to investigate 




The synergistic effect among different compartments can be 
experimentally validated. We can design an experiment that enables us to keep 
only one ppERK production pool. Cytosolic way is easy to get by double 
knockout both ksr and mp1 gene; while KSR-mediated way can also be 
achieved by adding plasma membrane location sequence to RasGTP or 
designing a adaptor for RasGTP on plasma membrane to construct a 
nanocluster targeted only to plasma membrane, which excludes the cytosolic 
way. To observe their combined response, we need only knockout mp1 gene. 
This combined response can then be compared with the individual outputs 
from KSR-mediated and cytosolic ERK activation subpathway to check the 
synergism between them.  Namely, whether the amount of ppERK when both 
cytosolic and KSR-mediated ERK activation are present, is greater, equal, or 
less than the arithmetic sum of the amount of ppERK when only cytosolic 
ERK activation is present, plus the amount of ppERK when only KSR-
mediated ERK activation is present, indicates the synergism, additivity, or 
antagonism relationship between the two ways of ERK activation. 
In the end of Chapter 2, we did some experimental exploration to 
elucidate the mechanism of MP1/p14 assembly ERK signaling modules under 
EGF stimulation. Our preliminary experiments observed that upon EGF 
stimulus, ERK localization is changed more to the cell edge when MP1 is 
overexpressed (Chapter 2). This indicates that MP1 might also have active 
role in directing ERK to the cell membrane at early time points, then facilitate 
ERK activation through cell membrane targeted scaffold proteins, e.g. KSR. 
Although this interplay of MP1 and KSR is not reflected in our modeling 
analysis, it could simply because of lack of data. Therefore, it would be 
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necessary to do further experiments on KSR- and MP1- mediated ERK 
activation kinetics to confirm this. Moreover, it would be interesting to extend 
the experiment on monitoring ERK activation and localization upon EGF 
stimulation (Section 2.4.4) with overexpressed KSR as well. Techniques such 
as RNAi and overexpression through transfection can be used, together with 
high resolution live cell imaging, to shed light on the spatial regulation of both 


















Chapter 4 Simulation of resistance 
evolution through combined drug targeting 
towards the EGFR-ERK pathway 
 
Parts of this chapter have been presented in the conference poster on 
Systems Biology in Human Disease 2012, Heidelberg, Germany. 
4.1 Abstract 
Drugs targeting the EGFR-ERK pathway have achieved significant 
anti-tumor effects, but clinical outcomes have been disappointing primarily 
because of post-treatment evolved drug resistance. A popular strategy for 
increasing anti-cancer efficacy is to use combination therapy, with particular 
focus on “synergistic,” combinations with greater than additive effect.   
By combining single cell pathway modeling with population level 
modeling, population level behavior of cancer cells can be deduced on the 
basis of that of individual cells. We constructed a mathematical model for the 
evolution of drug resistance in cancer cell populations with the EGFR-Ras-
Raf-MEK-ERK pathway of the individual cells inhibited by synergistic, 
additive, or antagonistic drug pairs. In this model, the temporal evolution of 
resistance is simulated through a discrete Gompertzian model of evolution in 
cancer cells under different drug combination treatments. The resistance 
evolution was measured by the growth rate of double mutant cells and the time 
for double mutant cells to dominate the population. 
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Our results showed that when using a synergistic drug combination, 
the evolution of resistance against an individual drug of the combination as 
well as the subsequent evolution of resistance against the second drug 
dominated the cancer cell population and developed faster than that treated 
with an antagonistic drug combination. While antagonistic drug combination 
in this pathway yielded an advantage over additive and synergistic drug 
combination therapy in terms of the onset of double drug resistant mutants and 
the subsequent expansion of such cells. We also noted that the time for the 
onset was negatively correlated to the turnover rate of cancer.   
Our studies suggested that, within the model assumptions, antagonistic 
drug combinations targeting this pathway are advantageous in delaying the 
onset of double drug resistant mutants and the subsequent expansion of such 
cells. Therefore, in addition to the conventional strategy for discovering 
synergistic drug pairs, it is of interest to study drug combination that 
antagonistically target EGFR-ERK pathway because they may delay the 









List of Terms used in Chapter 4 
 
Terms Defination Defined in 
section 
core module  Ras-Raf-MEK-ERK cascades in 
MAPK pathway 
4.2 
evolution fitness the ability for cells to both survive and 
reproduce 
4.2 
combined effect the combined inhibition effect of two 
drugs on the amount of activated ERK 
when both drugs are added to the cell 
4.2 
single effect the individual inhibition effect of one 
drug on the amount of activated ERK 
when the drug is used alone 
4.2 
combination efficacy the combined effect of two drugs relative 
to their single effect 
4.2 
NCE nature of combination efficacy 4.2 
DM double-mutant 4.2 
DM dominance the subpopulation of DM cells taking 
up more than ¾ of the whole cell 
population. 
4.2 
speed of resistance 
evolution 





the dynamics of cancer cells evolve and 




the influence of NCE on resistance 
evolution dynamics 
4.2 
NCE treatment The treatments of two-drug pairs with 
different NCE 
4.2 
synergistic treatment the treatment of a two-drug pair with 
synergistic combination efficacy 
4.2 
additive treatment the treatment of a two-drug pair with 
additive combination efficacy 
4.2 
antagonistic treatment the treatment of a two-drug pair with 
antagonistic combination efficacy 
4.2 
turnover rate It is assumed that the turnover of cancer 
cells is caused by cell proliferation and 
cell death. 
4.2 
low-turnover cancer P (proliferation rate) is small, and 




(death rate) to give the same overall 
growth rate 
high-turnover cancer P is large, but offset by high death rate D 4.2 
sensitive 
subpopulation 
the subpopulation of sensitive cells 4.2 
mutant1 
subpopulation 
the subpopulation of mutant1 cells 4.2 
mutant2 
subpopulation 
the subpopulation of mutant2 cells 4.2 
DM subpopulation the subpopulation of double mutant 
cells 
4.2 
EC50 the concentration of a drug that gives 
half-maximal effect  
4.3.2 
ED50 the effect level of 50% of maximal 
inhibition of the amount of activated 
ERK produced in the first 7200 seconds 
upon addition of EGF and drugs 
4.3.2 
CI combination index 4.3.3 
effective drug dose Drug-resistance was simulated as 
decreasing 90% of the respective drug 
dose 
4.3.4.1 
DRCE  dose ratio-dependent combination 
efficacy 
4.4.1 
critical turnover rate the particular turnover rate that shuts 















Cancers are usually caused by multiple genetic mutations, epigenetic 
abnormalities, and aberrant expressions. Despite this complexity, the 
proliferation of some cancer cells strongly depends on one oncogenic protein 
or pathway, which provides a basis for molecularly targeted therapy. The 
EGF-stimulated MAPK pathway is one important oncogenic pathway, where 
aberrations and mutations have led to uncontrolled cell growth in a high 
proportion of human cancers (Immervoll, Hoem et al. 2006; Kuhnen and 
Winter 2006). Many emerging therapies emphasize targeting proteins in this 
pathway. More than a dozen drugs in clinical trials including humanized 
antibodies and small molecule inhibitors have been developed to target the 
upstream pathway. Within the core module (Ras-Raf-MEK-ERK) of this 
pathway, small kinase inhibitors against Ras, Raf and MEK have also shown 
promising clinical results (Sebolt-Leopold 2000). 
However, one of the main causes of failure in the treatment of cancer is 
that cancer cells develop resistance as a consequence of being exposed to the 
drug for a certain period of time. Due to the innate genomic instability of 
cancer cells, new characteristics occur and accumulate with generations of 
development, thus, even a tumor composed of only sensitive cancer cells 
initially eventually acquires resistance to the drug during tumor progress 
(Nowell 1986). In this work, the term ‘evolution fitness’ is used to describe 
the ability for cells to both survive and reproduce. After the emergence of 
resistant cells, these cells will be able to escape from the suppression of 
proliferation by the drug and have higher evolution fitness with respect to the 
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wildtype sensitive cells. The higher evolution fitness for resistant cells will 
lead to continued disease progression and cancer relapse despite drug therapy. 
Clinical studies have revealed the various mechanisms of resistance that 
reduce the efficacy of drugs at reducing downstream hyperactive growth-
promoting effector proteins, e.g. active ERK in this pathway. Acquired 
resistance is a major challenge for drugs targeting this pathway (Suda, 
Mizuuchi et al. 2012; Yarden and Pines 2012). Mechanisms of resistance for 
EGFR-targeted therapies include second-site mutations, e.g. T790M (Scaltriti, 
Rojo et al. 2007), S492R (Montagut, Dalmases et al. 2012) in EGFR; MET 
amplification (Engelman, Zejnullahu et al. 2007; Yano, Wang et al. 2008); 
mutations in the same pathway, e.g. KRas mutation (Lievre, Bachet et al. 
2006); activation of compensatory pathways, e.g. the upregulation of NRG1 
(Yonesaka, Zejnullahu et al. 2011), IGF1R (Nahta, Yu et al. 2006), and the 
PI3K-AKT pathway (Engelman, Mukohara et al. 2006). 
Mechanisms of resistance include decreased drug import by loss of cell 
surface receptors (Hembruff, Laberge et al. 2008), deficiency in metabolism of 
converting pro-drug into its active form (Michael and Doherty 2005), 
alterations on oncogene and tumor suppressor gene expression (Qi, McTigue 
et al. 2011). For instance, enhanced receptor tyrosine kinase signaling as well 
as mutational activation of NRas has been reported to confer some melanoma 
patients resistance to pan-Raf inhibitor PLX-4032 (Nazarian, Shi et al. 2010; 
Villanueva, Vultur et al. 2010).  
A popular strategy for increasing efficacy of cancer treatment is to use 
combination therapy to delay the onset of resistance. The probability of cancer 
cells gaining resistance to combination therapy is lower because it takes 
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multiple mutations to develop resistance, and a multiple drug resistant cell is 
less likely to be present before the start of treatment. Thus increasing the 
number of drugs might cause cells unresponsive to single drug treatments to 
become responsive (Azmi, Wang et al. 2010). One use of such combination 
therapy to achieve long-term suppression in human cancers is to select drugs 
working on different mechanisms of action or targeting different species. The 
term ‘combined effect’ is used to define the combined inhibition effect of two 
drugs on the amount of activated ERK when both drugs are added to the cell. 
Similarly, the term ‘single effect’ is used to define the individual inhibition 
effect of one drug on the amount of activated ERK when the drug is used 
alone. The term ‘combination efficacy’ in our work is used to refer to the 
combined effect of two drugs relative to their single effect. The combination 
efficacy of two drugs can be additive, synergistic or antagonistic, meaning the 
combined effect is larger than, equal to or less than the sum of the single 
effects. There are several studies that investigate drug combinations on cancer 
treatment, especially synergistic drug pairs allowing a desired therapeutic 
effect to be achieved with a lower total drug dose (Greco, Bravo et al. 1995).  
However, multi-drug treatment including synergistic drug combination 
treatment has not yet been investigated for its impact on drug resistance.  
A study in E. coli found that the evolution of bacterial resistance was 
accelerated by synergistic antibiotic drugs, when compared with additive or 
antagonistic antibiotics (Hegreness, Shoresh et al. 2008). There might be a 
similar effect in cancer that is worth studying. Since bacteria and cancer cells 
differ in terms of multi-resistant clones’ proliferation, and given the fact that 
some anti-EGFR synergistic therapies in clinical use have shown significant 
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rates of acquired resistance, it would be worthwhile to investigate if the 
evolution of drug resistance will also discourage synergistic drug combination 
in cancer therapy. This could also help us answer the question whether the 
nature of combination efficacy (NCE) has any influence on the speed of 
resistance evolution.  
In this work, the term ‘double-mutants’ (DM) is used to refer to the 
subpopulation of cancer cells that show resistance to both drugs. It is assumed 
that resistance to both drugs only occurs via accumulation of two independent 
mutations and not one mutation that obviates both drugs. A single constant 
proliferation rate is also assumed for all DM cells regardless whether mutation 
1 or mutation 2 evolved first. The term ‘resistance evolution dynamics’ is 
used here to describe the dynamics of cancer cells evolve and develop 
resistance to drugs. We define ‘NCE-evolution relationship’ to mean the 
influence of NCE on resistance evolution dynamics, based on measurements 
such as how quickly the DM dominance occur, i.e. the subpopulation of DM 
cells taking up more than ¾ of the whole cell population. Two-drug pairs with 
different NCE (synergistic/additive/antagonistic) are applied to cancer cells, 
and compare the resistance evolution dynamics among different drug pair 
treatments. The treatments of two-drug pairs with different NCE will be 
referred to as different ‘NCE treatments’, the treatment of a two-drug pair 
with synergistic combination efficacy is referred to as ‘synergistic treatment’, 
the treatment of a two-drug pair with additive combination efficacy is referred 
to as ‘additive treatment’, and the treatment of a two-drug pair with 
antagonistic combination efficacy will is referred to as ‘antagonistic 
treatment’ in this work. 
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With the knowledge of NCE-evolution relationship, the most suitable 
drug combination scheme can be selected to delay the evolution of resistance 
to the longest possible period. It might then even reverse the selection process 
against resistant cells without significant reduction of the combined potency of 
the drugs. Eventually, this might help one to conquer the resistance barrier in 
cancer therapy.  
In addition, the variability of cancer also lies in the inherent turnover 
rates among various cancer types and patients. It is assumed that the turnover 
of cancer cells is caused by cell proliferation and cell death in this work. 
Clinically, the proliferation rates (P) and death rates (D) can be calculated 
from DNA-labeling data with the balance of these rates giving the overall 
tumor growth rate, simply denoted here as P-D. For example, breast cancer 
generally has low average proliferative and apoptotic probabilities of 0.00601 
and 0.00368 per cell (Liu, Edgerton et al. 2001), while B lymphocytes in 
bovine leukemia virus-infected sheep generally has a relative high turnover 
rate with average proliferation and death rate of 0.109 per day and 0.089 per 
day (Debacq, Asquith et al. 2002). In our work, proliferation is modeled using 
constant proliferation rates for each type of cell, meaning the P for each type 
of cell will not change during the evolution, but is different among different 
cell types. There are four cell types in this system: wildtype cell which is 
sensitive to both drugs, mutant1 cell which is resistant to single drug 1, 
mutant2 cell which is resistant to single drug 2, and double mutant cell which 
is resistant to both drug 1 and drug 2. In this work, they are referred to as 
‘sensitive subpopulation’, ‘mutant1 subpopulation’, ‘mutant2 
subpopulation’, and ‘DM subpopulation’, respectively. A same death rate is 
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assumed for all four types of cells on the assumption that each type of cell 
obeys certain cell growth rule. With a same overall tumor growth rate, there 
could be situations with various turnover rates: P is large, but offset by high 
death rate D, this represents a ‘high-turnover cancer’; P is small, and 
counterbalanced by a relative small D to give the same overall growth rate, 
this represents a ‘low-turnover cancer’. Interestingly, the treatment success 
and the pre-existence of resistant cancer cells are found largely dependent on 
cancer cell turnover rate for multi-drug therapies (Komarova 2006; Tomasetti 
and Levy 2010). Despite that, the influence of turnover rate on the emergence 
and propagation of resistant cancer cells after drug treatment remains unclear.  
Our simulation study was intended for studying whether different NCE 
treatments that targeting the EGFR-ERK pathway induce the emergence and 
the evolution of drug resistance at different speed. If so, also it would also be 
interesting to know which combination leads to slowest speed of resistance 
evolution while maintaining sufficient combined drug potency. 
While deterministic models can usually approximate real biological 
systems when there is a high copy number of molecules in the cell, at low 
copy numbers the effect of random fluctuations becomes significant. 
Stochasticity therefore needs to be taken into account to allow a faithful 
representation of the uncertainty and noise of the system (McAdams and 
Arkin 1997).  This is also the case when the rare mutation event is involved, 
because small numbers of rare events, rare proteins, or rare cells need to be 
tracked explicitly as the statistical laws of bulk treatment no longer apply. 
Stochasticity is considered here, because the number of mutated cell starts 
from 0, with low number of cells, the stochastic event will have significant 
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effect. Since the effect of drug combination is evaluated based on the time for 
double mutant cells to arise, the stochasticity has to be considered for the 
following development of the evolution model. 
A stochastic evolutionary model was therefore built to investigate and 
compare the resistance evolution dynamics in cancer cells with the EGFR-Ras-
Raf-MEK-ERK pathway under different NCE treatments. Furthermore, several 
control models with pathway independent drug targeting, and Gompertzian 
model independent exponential growth rule were also built, verifying that the 
EGFR-ERK pathway and Gompertzian parameters are not responsible for the 




4.3.1 EGFR Signaling Model 
We based our model of EGFR signaling on that of Hornberg et al., 
which itself is a refinement of earlier work. The model contains 103 chemical 
species, and 148 elementary reactions; these reactions are described as a series 
of ordinary differential equations based on the mass action law. The model is 
parameterized by 97 distinct reaction rate values and 103 initial conditions. 
The details of this model are given in (Hornberg, Binder et al. 2005). 
Here we also introduced a modified model of EGFR signaling, which 
contained six additional production/degradation reactions of the form of 
Equation (4-1), where X is one of <GAP, GRB2, SOS, RAS-GDP, SHC, or 
GRB2-SOS>. 
 
    
 
    
                                            (4-1) 
The degradation rate      was set such that the steady-state value of 
the species was the same as the steady-state value in the unmodified model 
computed using Equation (4-2). 
     
    
   
                                          (4-2) 
This augmented model has the additional property that if the input is 
removed (set to zero) it will return to its initial condition. 
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4.3.2 Drug targeting 
Drugs were simulated as each targeting specifically only one species. 
We simulate all possible drugs of all possible targets in the EGFR pathway 
model (Section 4.3.1). Drugs targeting each component in the EGFR signaling 
pathway were simulated as forming complexes with target components based 
on the mass action law. Constant stimulus of 5 nM EGF and drugs at indicated 
doses were added into the signaling pathway simultaneously, because we have 
no transport effects and everything is immediately available everywhere in this 
model. The EC50 was defined as the concentration of a drug that gives half-
maximal effect; and ED50 was defined as the effect level of 50% of maximal 
inhibition of the amount of activated ERK produced in the first 7200 seconds 
upon addition of EGF and drugs. 50% inhibition of ERK is used here as a 
measurement for effective drug inhibition, because cell growth is assumed to 
be proportional to active ERK amount in the cell (Asthagiri, Reinhart et al. 
2000). We are interested in the ERK amount within the first 7200 seconds, 
mainly because the activated ERK normally returns to quiescent level within 2 
hours in HeLa cells, and this time period is the common time scale employed 
for observations on effective growth factor induced ERK activation both 
experimentally and theoretically (Cruz, Neto et al. 2005; Hornberg, Binder et 
al. 2005). Additionally, this time period investigated is relatively small 
compared to the cell doubling time (for HeLa cells this number is at the scale 
of days per generation). 50% inhibition of ERK is used here as a measurement 
for effective drug inhibition, because cell growth is assumed to be proportional 
to active ERK amount in the cell (Asthagiri, Reinhart et al. 2000). The drug-
target dissociation constants Koff was set to be 0.01s
-1
, and the equilibrium 
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dissociation constant Kd is optimized to give the same EC50 dose of 10 nM, 
since much pharmaceutical research is aimed at designing nanomolar drugs 
(Lesuisse, Lange et al. 2002; Payne, Peyrot et al. 2007). 
4.3.3  Quantitative determination of combination 
efficacy  
Quantifying combination efficacy in drug combination studies and 
classifying the combination efficacy into categories of synergism, additivity, 
or antagonism are of interest to many researchers. Isobologram and 
combination index (CI) analyses are widely used methods for evaluating 
combination efficacy in combination cancer chemotherapy. Specifically, the 
Loewe additivity model has been largely used as a reference model when the 
combination efficacy of two drugs is additive. The model can be written as in 
Equation (4-3): 
    
     
 
    
     
                                        (4-3) 
where (D)1 and (D)2 are the respective combination doses of drug 1 
and drug 2 that yield an effect x, with (Dx)1 and (Dx)2 being the corresponding 
single doses for drug 1 and drug 2 that result in the same effect. When 
Equation (4-3) holds, it can be concluded that the combined effect of the two 
drugs is additive. One can easily check that Equation (4-3) holds in a “sham” 
experiment when the two drugs are identical. The Loewe additivity model is 
rooted in the use of the isobologram approach. Based on Equation (4-3), the 
interaction index, defined in Equation (4-4), can be used to classify drug 
combination efficacy as synergistic, additive, or antagonistic. 
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                                       (4-4) 
CI < 1 synergy; CI = 1 additivity; CI > 1 antagonism 
A CI of less than, equal to, and more than 1 indicates the combination 
efficacy is synergy, additivity, and antagonism, respectively.  
When the combined effect is lower than one of the single effects, it is a 
special case, defined as “super antagonism”. The isobologram for each drug 
pair at ED50 was drawn and shown in Figure 4-2.  
In this work, when study the NCE-evolution relationship, we 
specifically choose four drug pairs with different combination efficacy 
(synergism/additivity/antagonism). They are: a pair targeting MEK and EGFR 
(synergistic), a pair targeting MKP3 and PP2A (additive), a pair targeting Raf 
and Grb2 at intermediate Raf/Grb2 dose ratio (antagonistic), and a pair 
targeting Raf and Grb2 at low Raf/Grb2 dose ratio (super antagonistic). For 
the synergistic drug pairs inhibiting EGFR and MEK, we used the dose ratio 
that maximized the synergistic effect according to the CI at ED50. Similarly, 
for super antagonistic or antagonistic drug pairs inhibiting Raf and Grb2, we 
used the dose ratio that maximized the suppressive or antagonistic effect at 
ED50, according to the CI; for additive drug pairs, we used the dose ratio with 
similar single effects. 
4.3.4 Evolution dynamic modeling - Gompertzian model 
The evolution process of cancer cells was simulated through a 
stochastic model discretely generation by generation. There are four types of 
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cells in this system: wildtype cell, mutant1 cell, mutant2 cell, and double 
mutant cell.  
At each generation, cells undergo three phases: proliferation, mutation, 
and death. Each cell subpopulation can propagate at a proliferation probability 
in every generation. The proliferation probability is kept constant through the 
evolution, but different among different types of cells. During the proliferation, 
mutation could occur, and the mutation probability serves as the transition 
probability among four cell subpopulations. The overall growth of each cell 
subpopulation obeys the Gompertzian growth rule, which gives an overall 
growth rate that can infer the internal death probability for each cell. 
4.3.4.1 Phase I: Proliferation  
The cell proliferation probability of each cell per cell cycle was 
assumed to be dependent on ERK levels. The proliferation probability is 
assumed to be proportional to the ratio of the amount of active ERK after and 
before drug treatment: 
                  
                    
              
                                    (4-5) 
 
The amount of active ERK is computed using our refined model of 
EGFR signaling of Hornberg et al. (Method 4.3.1) 
                                   
    
 
                   (4-6)     
drug(i), where i = 1,2,3,4. denote  ‘effective drug dose’ sensed by 
sensitive cell, mutant1, mutant2, double mutant 
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                       denotes the time integral of ppERK under 
drug treatment for the cell from the ith category. 
                 denotes the time integral of ppERK without drug 
treatment.   
The proliferation probability is kept constant through the evolution, but 
different among different types of cells because of the ‘effective drug dose’ 
that each type of cell sensed.  
Hypothetical drugs were added as described above. Drug-resistance 
was simulated using the same ERK pathway model, but decreasing 90% of the 
respective drug dose as the ‘effective drug dose’.  
        =                             
        =                 
        =                 
        =                                                                      
                                               (4-7) 
 
The proliferation probability can also be obtained through other ways, 
not ERK level dependent, as has been simulated in Section 4.4.5.  
The cells can undergo mutation to switch other type of cell, therefore 
the mutation probability is the transition probability among the four cell types. 
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4.3.4.2 Phase II: Mutation 
A fixed mutation rate µ was assumed for generating mutations of 
single-drug resistance.  Double-drug resistance was simulated as two 
independent mutations of single-drug resistance. 
The probability of mutation to resistance per cell cycle is denoted as 
        , and the probability of mutation back to sensitive per cell cycle is 
denoted as          . 
                       
   (4-8) 
For every generation, after cells undergo proliferation and mutation 
phases, a pool of intermediate cells will be generated that will go through the 
death phase later.  
            =                     
                              
          =                   
               =                        
        =       
 
   
 
 = Nsensitive' + Nmutant1' + Nmutant2' + 
Ndoublemutant'                                                                                                                                            




Where prime symbol denotes the intermediate number of each cell 
types after the proliferation phase; Nmiddle denotes the total intermediate 
number of all four cell types. 
4.3.4.3 Gompertzian growth modeling 
The behavior of a cancer cell population was modeled with varying 
overall growth rate based on Gompertzian growth function (Norton 1988), 
which mimics the situation when tumor is under limited resources. The 
proliferation rate is modeled as constant during evolution, but is different 
among different type of cells. The total cell growth is then combined with 
proliferation rate to imply an internal death rate which varies as the tumor 
grows. 
In particular, the variation of total cancer cell population size by time 
is described by Gompertzian model as follows: 
            
  
 
           
                                     (4-10) 
Where A0 is the initial growth rate in biological time scale, and   is a 
constant for growth retardation. The initial growth rate A0 is the same as in 
exponential growth rate as described in Equation (4-11): 
                                                    (4-11) 
Hence, the time T required for N(t) to double, i.e. 
      
    
  , is always 
constant at 
   
  
 . The initial growth rate A0 can be then derived through tumor 
doubling time: 
   
   
 
                                     (4-12) 
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According to the Gompertzian model, the tumor cannot grow 
indefinitely, but asymptotically approaches a maximum level equal to 
      
  
 , when t→∞.       
   
           
  
  
So we have the relation,  
          
  
    
  
    
 
  (4-13) 
From Equations (4-10) and (4-13), we can get the time for the tumor 
to grow from N(0) till N(t): 
    
 
 
      
  
    
    
  
  
    
                                      (4-14) 
For untreated cancer cells, the selection of our initial growth rate A0 
and retardation factor   are within reasonable physiological range (at the scale 
of days) and give consistent prediction on survival time with the clinical tumor 
growth data empirically: The survival time is around 200 days to reach fatal 




), and 3 years to reach threshold level 




) (Speer, Petrosky et al. 1984; Monro and 
Gaffney 2009).  
Here, the doubling time T is set to be 5 days. Therefore, according to 
Equation (4-12) and Equation (4-13), we get the initial growth rate A0 = 
0.1386 day
-1
, and growth retardation constant   = 0.005 day-1. 
Growth rate for cancer cells under drug treatment: 
In the evolution model, the net growth rates for subpopulations of the 
four cell types can be deducted from Equation (4-10). From Equation (4-10) 
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above, we take time derivative of N, and get the growth rate for no drug 
treated cells: 
R  
     
  
                   
    
  
                            
                             (4-15) 
For the drug treated cells, the effect on suppression of cell growth 
is assumed to be proportional to the suppressed ppERK amount by drugs, 
therefore the growth rate for drug treated cells is: 
           
    
  
       
                    
              
       
                                                                           
where k =    is the scaling factor. 
I = 1,2,3,4. denotes  four categories of cells, respectively: 
sensitive cell, mutant1, mutant2, double mutant 
As has been defined in Equation (4-6), 
                                      
    
 
 
4.3.4.4 Phase III: Death 
By combining the growth Equation (4-16) based on Gompertzian 
model and the internal proliferation Equation (4-5) - (4-9), a unified death 
rate of cell can then be inferred: 
                 
 
   
               
 
   
 
                                                            (4-17) 
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4.3.5 Sensitivity analysis of parameters in the pathway 
model and evolution model 
The sensitivity of the simulation results with respect to the parameters 
were systematically analyzed to determine whether the model is sufficiently 
robust to make true predictions on the dynamic behavior of biological 
networks without the artifact of parameters. Here, the system feature is the 
time integral of ppERK in 7200 seconds (O), 
         
    
 
                                         (4-18) 
Where x is the species ppERK, t is the simulation time.  
The sensitivity (Sp) to a parameter p is: 











                                         (4-19) 
The sensitivity of the time integral of ppERK with respect to all 
parameters in the model was shown in Figure 4-1. Only 5 (4%) kinetic 
parameters including MEK dephosphorylation, ERK dephosphorylation and 
RasGDP related reactions showed some sensitivity, the majority of the 
parameters are insensitive in affecting the output. Thus, our model is 




Figure 4-1 Normalized parameter sensitivities toward the time integral 
of ppERK in 7200 seconds 
 
Furthermore, we examined the sensitivity of our stochastic evolution 
model with respect to parameters related to resistance evolution. The time to 
DM dominance was measured as the model output. The change of the model 
output with respect to the parameters were calculated and listed in Table 4-1.  
The sensitivity (Sq) to a parameter q in the evolution model is: 
   
  
  
                                         (4-20) 
Here, T is the model output: time to DM dominance.  
q is the parameters we perturbed, which are: N0 (the initial cell 
number); Nthreshold (the threshold cell number); the mutation probability; the 
tumor doubling time; and the resistance extent. 
Parameters were allowed to vary 5% around original values. We found 
that although the model output is changed when we perturb some parameters, 
the predominance of the four different drug combination treatments based on 




Table 4-1 Sensitivity analysis of parameters in evolution model 












Original time 679 376
 108 122 - 
Δ(N0) +35 -13 -4 -3 robust 
Δ(Nthreshold) +19 -4
 +23 +3 robust 
Δ(Mutation 
rate) 
+6 +12 +20 +3 robust 
Δ(Doubling 
Time) 
+30 +21 -3 -15 robust 
Δ(Resistance 
extent) 
-47 -6 +20 -15 robust 
 
4.3.6 Turnover rate modeling 
Cancer cell growth rate is the difference between total number of 
cancer cells in a unit time period, resulting from the inherent cell proliferation 
rate and cell death rate of cancer cells. Cancer cell turnover rate is different 
from the tumor growth rate, because tumor cells can have very fast 
proliferation combined with frequent apoptosis (high turnover rate) to yield 
the same net growth rate for the tumor, as another cancer with slower 
proliferation and less apoptosis (low turnover rate).  Cancer cell resistance 
evolution under targeted combination therapy with various turnover rates was 
simulated. For the sake of comparison, the overall growth rate was kept the 
same in all situations, only the proliferation rate was set to having folds 
change, thus the apoptosis rate will also change.  
      
                    
              
                                      (4-21) 
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Where q is the fold change of turnover rates  
P(i) denotes the proliferation probability under every drug treatment 
scheme, depending on the experiment design. 
 
4.3.7 Redundant drug targeting  
Two independent drugs that redundantly target the same species were 
considered (Section 4.4.4). By independent we mean the drugs have no 
cooperativity and no competition with each other. Therefore this simulates a 
situation where the two drugs have two independent (non-competitive, non-
overlapping, and non-allosteric) binding sites on the same enzyme. Regardless 
of the drugs or the targets, we assume the enzyme is 100% inhibited whenever 
bound to one or more of the inhibitor drugs.  In that sense, the drugs are 
redundant because after bound to one, binding to the other has no effect. 
Two pro-drug production reactions were simulated in the pathway. The 
two redundant drugs targeting MEK were simulated as produced from their 
respective pro-drugs, the pro-drugs were added to the system at indicated 
doses for 10 min. 
         
    
 
    
                                         (4-22) 
         
    
 
    
                                                         
For the simulations of redundant drugs in Section 4.4.4, we assumed 
both drugs would target MEK.  In that case, the hypothetical two drugs are 
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targeting MEK at different binding sites. Therefore, each Drug-MEK complex 
has the possibility of continuing to accept another drug at the other binding 
site, depending on its reaction rate. In other words, DrugX can bind to MEK 
and create an inhibited MEK:DrugX complex, but this complex can still bind 
to DrugY, to create a doubly-inhibited complex which is also inactive. Again, 
the drugs were assumed to obey the Law of Mass Action.   
         
   
 
   
                                                (4-24) 
         
   
 
   
                                                     
               
   
 
   
                                     (4-26) 
               
   
 
   
                                     (4-27) 
The existence of two different drugs binding onto different sites of 
MEK creates a less than additive effect.  This simulates a pair of redundant 
drugs with antagonistic effects as shown in Figure 4-11. A pair of cooperative 
drugs would be more antagonistic than the independent case shown here, and a 
pair of competitive drugs would be less antagonistic and closer to additive, 
than the case shown here. 
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4.3.8 Pathway-independent evolution modeling: assumed 
proliferation rates for different drug combination treatments 
In Section 4.4.5, we investigated NCE-evolution relationship through 
generic proliferation rates instead of ERK-based proliferation rates. We 
obtained the proliferation rates for 4 cell types as input to the evolution model, 
under the assumption that the drugs follow simple Michaelis-Menten kinetics 
and are mutually nonexclusive. In this case, the drugs have hyperbolic dose-
effect curves. 
When both drugs have hyperbolic dose-effect curves and are mutually 
nonexclusive, according to Webb’s method: the additive combined effect of 
unaffected fraction is the product of the unaffected fraction when treated with 
single drug 1 and unaffected fraction when treated with single drug 2. Webb’s 
method is applied to obtain proliferation probabilities for 4 cell types under 
certain assumptions. 
Since drugs are added to the system to eliminate a certain percentage 
of cells, there will still be a fraction of cells’ growth unaffected by the drug, 
which is defined as the unaffected fraction. The unaffected fraction is denoted 
here as     , i = 1, 2, 12, indicating the unaffected fraction under treatment of 
drug 1, drug 2, and drug 1, 2 in combination, respectively. 
According to Webb’s method, we have: 
                                                     (4-28) 
To facilitate comparison, the proliferation rates representing two 
situations are assumed: one is when the single drug effects on proliferation 
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inhibition are the same (Table 4-5); the other is when the combined drug 
effects are the same under all four types of drug combination treatments 
(Table 4-6). 
The two single drugs are assumed to have the same proliferation 
inhibition capability, then          . For the combination of drug 1, 2 to 
have 50% inhibition on cell proliferation,              . Through Equation 
(4-28), we could get: 
                                                             
Two assumptions we made are:  
(i) In low dose range, the combinations of drugs are considered to be 
always additive;  
(ii) 90% resistance on a certain drug is reflected on 90% reduction of 
proliferation inhibition for that drug, as indicated in Equation (4-30). 
                                                 (4-30) 
4.3.8.1 Assumed proliferation rates with the same single effect  
In situations indicated in Table 4-5, for wildtype cells under treatments 
of antagonistic, additive, and synergistic drug pairs, the single effects are the 
same but the combined effect are different.  For mutant1 cell which is resistant 
to drug 1, the inhibition effect of remaining drug 1 is 10% of the inhibition 
effect of total drug 1. Therefore, for single drug resistant mutant1, the 
proliferation rate is: 
                                               (4-31) 
For double drug resistant mutants, the proliferation rate is: 
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(4-32)             
We then set the proliferation rate based on that the combined effect is 
higher and lower than additive combined effect calculated through Equation 
(4-32), corresponding to antagonistic and synergistic drug pairs.  
4.3.8.2 Assumed proliferation rates with the same combined effect 
In situations indicated in Table 4-6, for wildtype cells under treatments 
of antagonistic, additive, and synergistic drug pairs, the combined drug effect 
are the same but the individual single drug effect are different.  The 
proliferation rates of single and double drug resistant mutants under additive 
drug pair treatments are calculated in the same way through Equations (4-28) 
to (4-32). The proliferation rates for single mutant and double mutant under 
treatments of other drug pairs are set to be lower and higher than the single 
effect from additive drug pairs (Equation (4-31)), corresponding to 
antagonistic and synergistic drug pairs. 
4.3.9  Exponential growth modeling of cancer cells  
In order to eliminate the influence from sophisticated parameters in the 
Gompertzian model, a cancer cell evolution model with constant final cell 
number was built (Section 4.4.6).  In the model we use here, the cells are 
growing exponentially with the death rate proportional to the difference 
between cell number at current generation and the threshold (10
12
, listed in 
Table 4-2).  
       
            
 
                                    (4-33) 
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The proliferation probability and mutation probability are kept the same 
as previously used in the Gompertzian model. Thus the total cancer cell 
population will increase very fast to the threshold and remain constant at the 
threshold level. 
4.3.10   Drug combination administration schedule 
comparison: simultaneous versus sequential treatment 
Different drug combination administration schedules are also evaluated  
(Section 4.4.7) through comparing the speed of resistance evolution in cancer 
cells.  
For simultaneous treatment, cells were treated with both drugs together 
at the beginning of the simulation in the presence of a constant 5 nM EGF 
stimulus, the two drugs (EGFR inhibitor and MEK inhibitor) are added at the 
ED50 level. 
For sequential treatment, drugs were added in two steps: Cells were 
exposed to Drug1 first for a certain amount of time, then we changed Drug 1 
to (Drug1+Drug2) combination, aiming to comparing the timing of 
introducing the second drug in combination. In the presence of a constant 
stimulus of 5 nM EGF, cells were first exposed to EC50 dose of EGFR 





, which corresponds to 1% or 10% of the initial cell number. 
Then the drug scheme was changed to be composed of drugs targeting MEK 
and EGFR (2.3843nM Drug1 targeting MEK and 2.8478 nM Drug2 targeting 
EGFR, NorCI=0.5545) at ED50 level. 
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The speed of resistance evolution under sequential treatment was then 
compared with that under simultaneous treatment at ED50 effect level. 
4.3.11 Comparing resistance evolution dynamics and 
statistical analysis 
In order to investigate the NCE-evolution relationship, we seek for 
measurements to describe the speed of resistance evolution in cancer cells.  
Four measurements were taken in Section 4.4.2 to 4.4.7 to depict the 
resistance evolution dynamics in cancer cells.  
1. The time for double mutant cells to arise;  
The number of generations required before the first double mutant cell 
to appear is defined as the time for double mutant cells to arise. 
2. The time for double mutant cells to start expanding 
There are challenges to overcome during cell propagation due to cell 
type transformations and suppression from the drug, mutant cells might appear 
and disappear, then appear again, etc. The number of generations for the 
double mutant cell number to start stably and continuously increase is defined 
as the time for double mutant cells to start expanding. 
3. The time to DM dominance in the cell population 
DM dominance is defined as when the double mutant cell population 
composes more than ¾ of the whole cancer cell population. 
               3/4×(Nsensitive + Nmutant1 + Nmutant2  
+Ndoublemutant)                                          
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                                                            (4-32) 
4. The total cell number after 500 generations  
The sum of cell numbers of sensitive cells, mutant1 cells, mutant2 cells 
and double mutant cells at the 500th generation was calculated as the total cell 
number after 500 generations. 
Statistical analysis: 
The stochasticity in our evolution system comes from the randomness 
of mutation event during cancer cell evolution in every generation. This is 
simulated through random number generator in matlab (2012b version).  
The four measurements mentioned above were counted, and data from 
three replicates based on random number generator variation were collected. 
Each experiment was conducted three times with varying the seed for random 
number generator to simulate the three replicates. Statistical mean, standard 
deviation from the three replicates were calculated, and one-tailed unpaired t 
tests were performed to compare the values of every measurement under four 
different combination treatments. A P value < 0.05 was considered significant 
for all analyses. All data are expressed as means ± SD. 
4.4 Results and Discussion 
4.4.1 Synergism, additivity and antagonism appear when 
pairs of drugs target the EGFR-Ras-Raf-MEK-ERK pathway 
We first constructed a framework for classifying pairs of targeted 
drugs as synergistic, additive, or antagonistic.  This classification is applied to 
an exhaustive range of hypothetical drugs that inhibit every possible species in 
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the EGFR-ERK pathway model (Method 4.3.1), and the combined effect of 
drugs targeting every pair of proteins in the pathway is examined. We 
simulated isobolograms for each pair of drugs with eight equally effective 
dose combinations for a particular effect level, and compared the drug doses 
when used in combination to the drug doses when used individually, to infer 
synergism, additivity, and antagonism.   
Specifically, a particular effect level of ED50 (Method 4.3.2) is 
selected. In this system, we have defined the biological effect to be the 
cumulative amount of active ERK during the first 7200 seconds after EGF 
stimulation, because of the reasonable assumption that the amount of DNA 
synthesis is linearly proportional to the time integral of ERK activity 
(Asthagiri, Reinhart et al. 2000). Doses of drug 1 and drug 2 that give this 
effect are plotted as axial points in the isobologram graphs. In particular, a 
classic isobologram is established on a coordinate system composed of the 
actual individual drug doses, while a dose-normalized isobologram for two 
drugs is also constructed. The dose-normalized isobologram is based on 
normalization of actual drug dose with the respective EC50 to unity on both x- 




Figure 4-2 The selected dose-normalized ED50 isobolograms of 
combination therapies targeting the EGFR-Ras-Raf-MEK-ERK pathway.  
The y axis indicates inhibition of the named species, and the x axis indicates 
inhibition of the named species. The highlighted combination pairs are the 
three representative pairs randomly selected for use in the following evolution 
simulation. Their detailed isobolograms based on absolute drug dose are 
described in Figure 4-3. 
 
Isobologram curves in Figure 4-2 show the different drug dose 
combinations at ED50 effect level. The isobologram curves are expected to be 
parallel to the diagonal for independent drug pairs, concave for synergistic 
drug pairs, and convex for antagonistic drug pairs, according to Loewe 
additivity. We use the combination index (Method 4.3.3) to quantify the 
shapes of isobologram contours where values near 1 indicate additivity 
(independence), values smaller than 0.9 indicate synergy, and values larger 




Figure 4-3 The example classic ED50 isobolograms for two drugs with 
actual doses on the x- and y- axis. 
(A) The classic ED50 isobologram of dual targeting of EGFR and MEK, an 
example of synergistic drug interaction. (B) The classic ED50 isobologram of 
dual targeting of phosphatases MKP3 and PP2A, an example of additive drug 
interaction. (C) The classic ED50 isobologram of dual targeting of Raf and 
Grb2, an example of antagonistic drug interaction. The doses indicated in the 
figures are actual drug doses used in combination.  
 
Synergistic treatments have been explored in cancer therapy because of 
their higher efficacy (Greco, Bravo et al. 1995). This higher efficacy is also 
reflected in the lower total dose required to achieve a certain therapeutic effect, 
when compared to additive treatments and antagonistic treatments. From the 
classic combination curve on targeting EGFR and MEK with absolute drug 
dose value (Figure 4-3), we found a synergistic pair required the lowest total 
drug dose (~5nM) to achieve the same ED50 effect. In comparison, to achieve 
ED50 effect, the total drug dose required is about 10nM when using an 
additive pair of drugs targeting MKP3 and PP2A, and 18nM when using an 
antagonistic pair targeting Raf and Grb2. The data analyzed is the third drug 
dose combination denoted on the combination curves in the classic 
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isobolograms (Figure 4-3), with Drug1 dose (target at named species 
indicated on the x axis) to be 28.57% of the respective EC50 dose. The 
reduced amount of drugs used sometimes indicates lower side effects and 
cytotoxicity empirically (Galway, Morrison et al. 1973). 
Different dose combinations for the same drug pair can sometimes 
produce entirely different combination efficacies, such as one pair of doses 
producing synergistic effect but another pair of doses producing antagonistic 
effect. We define this phenomenon as these drugs showing dose ratio-
dependent combination efficacy (DRCE).  In our drug combination study, 
we found the drug pair targeting Raf and Grb2 showed DRCE (Figure 4-3C), 
with the combination efficacy ranging from super antagonism, antagonism to 
additivity. For drug pairs with DRCE, it is important to predict the specific 
combination dose ratios that yield a particular level of effect through the 
computational model. Thus, the dose ratio of these two drugs targeting Raf 
and Grb2 has to be specified with regards to a certain combined effect.  
We also noted that many drug combinations that included EGFR 
inhibition showed significant synergy, but to different extents, even when the 
other targets was all within the core module (Ras-Raf-MEK-ERK) of the 
MAPK network (Figure 4-2, row 5). The drug combination targeting EGFR 
and MEK is found to be synergistic, which is consistent with the findings in 
several published experimental studies (Balko, Jones et al. 2009; Yoon, Kim et 
al. 2009; Diep, Munoz et al. 2011). However, these combined anti-EGFR 
therapies in clinical use sometimes show significant rates of acquired 
resistance despite the high efficacy. Therefore it is beneficial for 
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understanding this phenomenon by studying resistance evolution dynamics in 
cancer cells treated with combination treatments.  
 
4.4.2 Different evolution resistance dynamics arise 
under different NCE treatments with the same combined effect 
We next study whether the NCE of a drug pair 
(synergism/additivity/antagonism) influences the speed at which a population 
of cancer cells will develop resistance. The temporal evolution of the drug 
resistance in cancer cells is simulated through a discrete model of evolution 
generation by generation. A cell in the system has proliferation probability to 
propagate itself and mutation probability to generate resistance to drugs. We 
assume a same single proliferation probability for the same type of cells. The 
cells might gain of lose the resistance to a drug at the mutation probability. At 
most one mutation event is allowed to occur to each cell in one generation. 
Two-drug resistance was assumed from the accumulation of two independent 
random mutation events. All four types of cell will also undergo cell death. 




Figure 4-4 Workflow of the systematic procedure to simulate cancer 
cell evolution under drug combination treatment 
 
Hypothesized drugs were simulated targeting each component in the 
EGFR signaling pathway. The drug-target dissociation constants Koff was set 
to be 0.01s
-1
, and the equilibrium dissociation constant Kd is optimized to give 
the same EC50 dose of 10 nM, since much pharmaceutical research is aimed 
at designing nanomolar drugs (Lesuisse, Lange et al. 2002; Payne, Peyrot et al. 
2007) (Method 4.3.2). A combination of two drugs was added into the EGFR-
ERK pathway (Figure 4-4A). Through the model of EGFR-ERK pathway 
under NCE treatments, the biological response of active ERK from the 
pathway was computed (Figure 4-4B). The proliferation rate of cancer cells 
was assumed to be proportional to the amount of active ERK  (Figure 4-4C). 
There are four cell types in this system: wildtype sensitive cell, mutant1 cell, 
mutant2 cell, and double mutant cell. The ‘effective drug dose’ sensed by the 
drug resistant cell was simulated as decreasing 90% of the respective drug 
dose (Method 4.3.4.1).  
The evolution process of drug resistance is simulated through a 
discrete model generation by generation. The initial cell number at the 
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beginning of drug treatment is assumed to be 10
9
, corresponding to a tumor 
with 1.0 cm diameter (James, Eisenhauer et al. 1999; Schreiber, Arina et al. 
2012) (Table 4-2). The initial cell population was assumed to be only 
composed of wildtype sensitive cells. They stay sensitive but acquire various 
mutations until some set of mutations allows them to exhibit resistance. 
Therefore, the mutation probability is simulated as the simplistic transition 
rate among the four cell types. Each cell subpopulation has its own 
proliferation probability, which increases the population size after every 
generation. Due to the difference in the “effective drug dose” sensed by the 
four cell types, the proliferation probability for each cell type differs (Figure 
4-4C).  
In each generation, cells undergo three phases: proliferation, mutation 
and death (Figure 4-4D). In proliferation phase, each type of cells divide at 
the probability calculated from ERK activation under the “effective drug dose” 
treatment. In mutation phase, the forward and backward mutation rate is 
assumed to be the same (Table 4-2). Mutations occur during cell proliferation, 
and the double mutation is simulated as accumulation of two random mutation 
events. After going through the proliferation and mutation phases, all four 
types of cells will then undergo the death phase with a same internal death rate. 
Methods subsection 4.3.4.4 describes how we compute a death rate for each 
timepoint, and apply it to the 4 cell types.  The death phase serves to limit the 




The parameters and variables included in the simulation model are 
listed below (Table 4-2). All other specifications of the model can be found in 
Method 4.3.4.   
Table 4-2 A list of parameters and variables included in the model 
Symbol Interpretation Value Meaning Reference 
N0 Initial cell number 10




et al. 1999) 
Nf Fatal cell number 10





N∞ Saturating number of 
cells in absence of 
therapy 





µforward Mutation to resistance 
per cell cycle 
10-6 - (Goldie and 
Coldman1998) 
µbackward Back mutation to 
sensitivity per cell 
cycle 




In order to compare and study the NCE-evolution relationship, 
different NCE treatments (synergism/additivity/antagonism) were applied to 
the EGFR-ERK pathway (Figure 4-4A). Specifically, four drug pairs were 
used: a pair targeting MEK and EGFR (synergistic), a pair targeting MKP3 
and PP2A (additive), a pair targeting Raf and Grb2 at intermediate Raf/Grb2 
dose ratio (antagonistic), and a pair targeting Raf and Grb2 at low Raf/Grb2 
dose ratio (super antagonistic). The details of quantitative determination of 





Figure 4-5 Evolution patterns of cancer cells under four different NCE treatments 
(A) Super antagonistic treatment; (B) Antagonistic treatment; (C) Additive treatment; (D) Synergistic treatment. 
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Table 4-3 Proliferation probabilities generated from the EGFR-ERK pathway 
 
Cell type/ Proliferation 
rate/drug 
Super antagonistic pair  
 
2.2621 nM Drug1 (Raf) 
+ 19.408 nM 
Drug2(Grb2). 
NorCI=1.98920 
Antagonistic pair  
 
3.0162 nM Drug1 (Raf) + 




5.4163nM Drug1 (MKP3) + 




2.3843nM Drug1 (MEK) 
+ 2.8478 nM 
Drug2(EGFR). 
NorCI=0.5545 
Wt+drug1+drug2 0.5000 0.5000 0.5000 0.5000 
Mutant1+10%drug1+drug2 0.4819 0.4909 0.6362 0.7422 
Mutant2+ drug1+10%drug2 0.6086 0.6342 0.6384 0.7665 
DoubleMutant+10%drug1+10%
drug2 
0.6267 0.6728 0.8949 0.9507 
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Although experimental observations can give certain measures of 
tumor evolution and dynamics, such as tumor size and tumor doubling time, 
the internal evolution dynamics within the tumor cell population during 
therapy is difficult to measure. This is particularly the case when the mutant 
cell population is below a detectable level. Our stochastic cell evolution model 
provides us the internal competition among different cell subpopulations. 
Simulation was performed with a fixed mutation rate under continuous four 
NCE treatments. The time resolved dynamics of the four types of cells 
(sensitive cell, mutant1, mutant2, double mutant) are depicted by four colored 
curves in Figure 4-5. It clearly shows four different cell evolution patterns 
under different NCE treatments (super antagonism/ antagonism/ additivity/ 
synergism).  
Since we assumed a fixed mutation rate per cell per generation and 
doses of combined drugs are added to cause the same proliferation inhibition 
(50% inhibition of ERK activation amount) on wildtype sensitive cells, 
nothing affected the number of generations before the first mutation of drug-
resistance arose (Figure 4-5A to D, the red and green lines). In contrast, the 
four drug combination pairs have different proliferation inhibition capability 
on the other three mutated cell types, depending on whether they are additive, 
synergistic, or antagonistic. Table 4-3 shows the proliferation rates of the four 
cell types. Note that there were large differences in the rate at which double 
resistant subclones expanded. Thus under different NCE treatments, the 
relative evolution fitness of single or double resistant cells with respect to 
sensitive cells are different. These differences in relative evolution fitness 
cause differences in the time for double mutant cells to arise and expand 
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across cell population (Figure 4-5A to D, the blue lines). In particular, 
viewed from the intersections between the colored lines and the black dashed 
line y = 10
9
, the time required before the denoted cell type reach the number of 
10
9
 vary among treatments of four different drug combination schemes. When 
under super antagonistic treatment, the times required for single mutant and 
double mutant to propagate till 10
9
 is 180 and 536 generations, respectively; 
when under antagonistic treatment, the times required for single mutant and 
double mutant to propagate till 10
9
 is 146 and 318 generations; while in 
contrast, when cells are under additive or synergistic treatment, both single 
and double mutants reach 10
9
 within 120 generations. This difference in the 
time for single and double mutant cells to evolve to a certain number 
demonstrates that the speed of resistance evolution varies. The speed of 
resistance evolution is highest when under synergistic treatment. The arrows 
(at the highest intersection between the blue line and the other lines) indicate 
the time required for the DM subpopulation to be larger than the other cell 
subpopulations. Therefore, it is obvious that cancer cells with synergistic 
treatment evolved population-wide resistance to both drugs, 3 to 5 fold more 
quickly than cells with antagonistic treatment (arrows, Figure 4-5).  
In summary, this model indicates that whenever resistance against a 
single drug dominated the population quickly, the subsequent evolutionary 
process had more opportunities for resistance against the second drug to arise 
in cells that already had the first mutation, rather than creating another single-
mutation subclone. Resistant cells dominated the population more quickly 
when cancer cells are under synergistic treatment, since it created a larger 
relative difference in evolution fitness. Moreover, there might also be 
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differences in ultimate cell numbers, as we noted that after 2000 generations, 
the super antagonistic and antagonistic treatments will control cell number to 
be around 10
9
; while additive and synergistic treatments will cause cell 
number to grow to 10
11 
(Figure 4-5, the blue lines).  
 
4.4.3 The effects of cancer cell turnover rate on the 
evolution of resistance to drug combinations 
One of cancer’s variabilities lies in the different internal cancer cell 
turnover rate (proliferation versus apoptosis rate). The turnover rate is 
different from the tumor growth rate because tumor cells can have very fast 
proliferation combined with frequent apoptosis to yield the same net growth 
rate of another cancer with slower proliferation and less apoptosis. The cancer 
cell turnover rate under multi-drug therapies is closely related to the pre-
existence of resistance before treatment (Komarova 2006; Tomasetti and Levy 
2010). However, it is unclear how the growth and evolution of resistant cells 
under various NCE treatments is dependent on cancer cell turnover rate. In 
determining the correlation between the resistance evolution dynamics and 
cancer cell turnover rate, the NCE treatment which is most effective on 
inhibiting the growth of resistant cells can be selected. This has profound 
implications in the selecting of drug therapies for treatment in cancer patients.  
In order to investigate the correlation between the cancer cell turnover 
rate and the resistance evolution dynamics, we applied the above built 
stochastic evolution model to cancers with various turnover rates. In the 
evolution models of low-turnover cancers, the initial proliferation rates were 
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simulated as folds lower than the proliferation rates in high-turnover cancers 
(Method 4.3.6). The difference in the initial proliferation rate and 
proliferation rate during drug treatment can give us insights into the different 
resistance evolution dynamics.  
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4.4.3.1 Simulations of resistance evolution in low-turnover cancer cells 
 
Figure 4-6 Evolution patterns of low-turnover cancer cells under four different NCE treatments 
In a low-turnover cancer (q = 1/20), cancer cell evolution patterns are different when under (A) super antagonistic treatment, (B) 
antagonistic treatment, (C) additive treatment and (D) synergistic treatment 
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The evolution pattern of low-turnover cancer cells under the treatment 
of different drug combination schemes are shown in Figure 4-6. Cancer cells 
with the same overall growth rate but a lower turnover rate have a slower 
evolution due to the lower proliferation, mutation and death rates. In contrast 
to the high-turnover cancer, the resistance evolution dynamics in low-turnover 
cancer is much slower in terms of time for single and double resistant mutant 
to arise, and the fitness advantage of the DM cell over single mutant cell and 
sensitive cell becomes more apparent as turnover rate decreases. Nonetheless, 
the order of predominance of the four NCE treatments according to time for 
resistance to arise is unchanged: super antagonistic treatment > antagonistic 
treatment > additive treatment > synergistic treatment.  
The difference in resistance evolution dynamics under various NCE 
treatments is also reflected in the time for DM subpopulation to be the largest 
in the cell population. It takes longer than 5000 generations before DM 
subpopulation become the largest subpopulation when cancers are under super 
antagonistic or antagonistic treatments; while when under additive or 
synergistic treatments, DM subpopulation becomes the largest subpopulation 
within 3000 generations (Figure 4-6, arrows). This indicates that antagonistic 
treatment is more effective than synergistic treatment in delaying resistance 






Figure 4-7 Evolution patterns of cancer cells with very low turnover 
rate under four different NCE treatments 
In low-turnover cancer (q < 1/25), cancer cell evolution patterns when 
under (A) super antagonistic treatment, (B) antagonistic treatment, (C) 
additive treatment and (D) synergistic treatment 
 
In high-turnover cancers, the speed of resistance evolution is the 
smallest when cancer cells are treated with antagonistic treatments, and the 
largest when cancer cells are treated with synergistic treatments. This NCE-
evolution relationship holds in turnover rates higher than the critical turnover 
rate, i.e. the particular turnover rate that shuts down the resistance evolution, 
which as shown from simulation, is different when under different drug 
combination treatments. When the cancer cell turnover rate is lower than the 
critical turnover rate, the mutation rate for resistance will also be low, because 
it is proportional to the proliferation rate. Only a small number of resistant 
cells will appear, and the size of DM subpopulation is small enough to be 
eliminated by any types of drug combination. Thus, there is no difference 
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between the treatment effects of these two combinations in cancer cells with 
very low turnover rate. Both will control total cell number at low level of 
around 8 × 10
8
 (Figure 4-7).  
 
4.4.3.2 Investigations on the relationship between cell turnover 
rate and resistance evolution 
Through simulating drug combinations in cancers with variable 
turnover rate, the dependency of the selection of drug combination scheme on 
the inherent turnover rate of cell population can be revealed. The detailed 
relationships between resistance evolution and turnover rate are displayed in 
the following figures (Figures 4-8 to 4-10). Four measurements were taken to 
depict the relationship between resistance evolution dynamics and cancer cell 
turnover rate (Method 4.3.11).  
i. The time for double mutant cells to arise;  
ii. The time for double mutant cells to start expanding; 
iii. The time to DM dominance;  
iv. The total cell number after 500 generations  
Data on these four measurements are collected from three replicates 
through random number generator variation. These measurements will give 
hints on how inherent turnover rate affects the speed of resistance evolution 
and thus the selection of drug combination scheme (Method 4.3.11). 
(a). Investigation of the time for double mutants to arise in cancers 




Figure 4-8 Diagram of the relationship between the speed of resistance evolution and cancer cell turnover rates 
(A)Relationship of time for double mutant cells to arise versus cancer cell turnover rates under four different NCE treatments; (B) scattered bar 
graph of time for double mutant cells to arise versus cancer cell turnover rates under four different NCE treatments; (C) relationship of time for 
double mutant cells to start expanding versus cancer cell turnover rates under four different NCE treatments; (D) scattered bar graph of time for 
double mutant cells to start expanding versus cancer cell turnover rates under four different NCE treatments. Data are presented as mean ± SD 
obtained from three replicates. Here, R is the proliferation probability for every cell every generation,    
                 




The relationship between the resistance evolution dynamics under 
different NCE treatments and cancer turnover rate is essential for 
understanding the role of this internal cancer turnover rate in the selection of 
drug combination scheme. Figure 4-8A and C indicate that both the time 
required for double mutant cells to arise and start expanding are negatively 
correlated with the turnover rate, especially when the turnover rate is low 
(proliferation probability < R/5). The data is also shown in bar graph and is 
listed in respective tables in Figure 4-8B and D, correspondingly.  Through 
comparison of the time required for the first double mutant cell to arise and the 
time required for double mutant cells to start expanding, we found that in 
high-turnover cancers, antagonistic drug combinations in the EGFR-ERK 
pathway yielded an advantage over synergistic drug combination therapy, and 
this difference on timing is more obvious in low-turnover cancers.  
Interestingly, there is no significant difference in the time for double 
mutant cells to arise among super antagonistic, antagonistic and additive 
treatments. The time for  double mutant cells to start expanding across the cell 
population are highly significantly different among four NCE treatments 
(unpaired t test, p<0.01) in cancers with proliferation probability lower than 
R/5. It takes the longest time for double mutant cells to start expanding when 
under antagonistic treatment (Figure 4-8D). For example, in cancers with low 
turnover rate (proliferation probability = R/20), the times required for double 
mutant cells to arise range from 1100 to 1300 generations when under super 
antagonistic, antagonistic and additive treatments (Figure 4-8B, bar group at 
R/20); while in cancers with the same turnover rate (R/20), the time required 
for double mutant cells to start expanding is apparently longer when under 
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super antagonistic treatment (2055 ± 48 generations) than that when 
antagonistic (1782 ± 174 generations), additive (1502 ± 35 generations) and 
synergistic treatments (849 ± 24 generations). Furthermore, through 
comparison between Figure 4-8B and D, we noted that the time delay for 
double mutant cells to start expanding after they arise is shorter in cancer cells 
with synergistic treatment than those with antagonistic treatment. For example, 
simulations in cancer with low turnover rate (proliferation probability = R/20) 
showed that, when under a synergistic treatment, the first double mutant cell 
arose after 665 ± 67 generations, and it started propagating and expanding 
after 850 ± 24 generations, the time delay was 185 generations on average (p < 
0.05); When under additive, antagonistic and super antagonistic treatments, 
this time delay becomes 382, 473, and 743 generations in average (p < 0.01), 
respectively. This result can be explained by the similar proliferation 
probability for single mutant cells and the large difference on the proliferation 
probability for double mutant cells under different NCE treatments (Table 4-
3). The large difference in proliferation probability between double mutant 
cells and single mutant cells create high evolution fitness of full resistant cells 
to partial resistant cells, thus it is relatively easy for a double mutant cell to 




(b). Investigation on the time to DM dominance in the cell 
population 
The composition of the cell population after a period of time can reveal 
the relative evolution fitness among partial and fully resistance cells, sensitive 
cells in the cell population. Therefore, except from the time for double mutant 
cells to arise and expand, the relationship between the time to DM dominance 
in the cell population and cancer cell turnover rate is investigated in our study 
(Figure 4-9). Time to DM dominance was defined as the number of 
generations required for the double mutant cell population composes more 
than ¾ of the total cell population. The time to DM dominance is negatively 
correlated to cell turnover rate, especially in low turnover rate range with 
proliferation probability for sensitive cells smaller than R/2 (Figure 4-9). 
There is no significant difference on this timing for cells under additive and 
synergistic treatments in all turnover-rate cancers, but they are 3 fold and 6 
fold faster than that in cells under antagonistic and super antagonistic 





Figure 4-9 Diagram of the relationship between the time to DM 
dominance and cancer cell turnover rates   
(A)Relationship of time to DM dominance in the whole cell population versus 
cancer cell turnover rates under four different NCE treatments; (B) scattered 
bar graph of the time to DM dominance versus cancer cell turnover rates. Data 
are shown as mean ± SD obtained from three replicates. Here, R is the 
proliferation probability for every cell every generation, 
   
                 







(c). Investigation on the total cell number after 500 generations 
under various NCE treatments 
The total cell number including all four cell types after drug treatment 
for 500 generations is also considered as a measurement for drug combination 
scheme selection, because the total cell number is an indication for the tumor 
size. As shown in Figure 4-10A, the total cell number increases with 
increased turnover rate. In our simulation, cancer cells under synergistic and 
additive treatments increased in number much faster than those under 
antagonistic and super antagonistic treatments in the first 500 generations, and 
will expand until fatal level in high-turnover cancers (cell number larger than 
10
11
), while antagonistic and super antagonistic treatments will control cell 
number to be under 10
10





Figure 4-10 Diagram of the relationship between the total cell number 
after 500 generations and cancer cell turnover rates   
(A)Relationship between the total cell number after 500 generations and 
cancer cell turnover rates under four different NCE treatments; (B) scattered 
bar graph of the total cell number after 500 generations versus cancer cell 
turnover rates. Data are shown as mean ± SD obtained from three replicates. 
Here, R is the proliferation probability for every cell every generation, 
   
                 
              
.  
 
In summary, in terms of the time for double mutant cells to arise and 
expand, the time to DM dominance and the total cell number after the same 
number of generations, our simulations suggest that, within our model 
assumptions, there is a noticeable advantage of antagonistic treatment over 
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additive and synergistic treatment for cancer therapy, especially in low-
turnover cancers. 
4.4.4 The resistance evolution to pairs of drugs, when 
the individual drugs have the same efficacy  
An obvious benefit of synergistic treatment is that they allow drugs to 
achieve higher net efficacy without increasing the individual drug doses.  Our 
simulations above (Sections 4.4.2 and 4.4.3) compared combination 
treatments where each candidate combination had the same combined effect 
on proliferation inhibition, and the only differences were in the single effects. 
Even though this created a level playing field for all combinations, it is 
unrealistic. In reality, a synergistic treatment would have greater efficacy and 
stronger suppression of proliferation than additive or antagonistic treatment.  
Therefore we next performed a series of experiments in which the single 
effects were the same but the combined effects were allowed to vary – with 
greater effects for synergistic treatment and lesser effects for antagonistic 
treatment.  This creates an advantage for synergistic treatment, but it 
represents a more realistic comparison. The individual single effect for every 
drug was assumed to cause 30% inhibition of active ERK. Each drug dose was 
calculated from their respective dose-effect relationship through the pathway. 
We used the three combinations studied above (Section 4.4.2), namely the 
drug pair targeting MEK and EGFR (synergistic), the drug pair targeting 
MKP3 and PP2A (additive) and the drug pair targeting Raf and Grb2.  Note 
that the ED50 isobologram for Raf and Grb2 shows antagonism only for 
certain dose ratios (see Figure 4-3C).  In previous studies with the Raf Grb2 
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pair, we chose a dose ratio that caused antagonism in the combined effect on 
ppERK in sensitive cells, but such a choice of dose ratio violates the current 
requirement that the single effects should all be the same.  When we give Raf 
and Grb2 inhibitors with equal single effects, the combined effect is nearly 
additive and not highly antagonistic.   
To provide an antagonistic example, we introduced another type of 
drug pair in addition to the previous three combinations.  We postulated the 
existence of two different drugs that both target MEK, but with different 
binding sites so they do not compete with each other.  In other words, drug1 
can bind to MEK and create an inhibited MEK-drug1 complex, but this 
complex can still bind to drug2, to create a doubly-inhibited complex which is 
also inactive. This simulates a pair of drugs with redundant effects.   
The two redundant drugs targeting MEK were simulated as a pulse 
stimulus for 600 seconds (Method 4.3.7). All other specifications of the 
resistance evolution modeling are the same as the constructed Gompertzian-





Figure 4-11 The dose-normalized ED50 isobologram of two redundant 
drugs targeting MEK in the EGFR-ERK pathway 
The convex shape of the isobologram curve indicates antagonism interaction 
between these two drugs. Normalized Combination Index is larger than 1. 
 
Redundant drugs do not negate each other and are not super 
antagonistic, but they are significantly less effective than additive, as shown in 
the ED50 isobologram in Figure 4-11. 
When we simulated the combined effect on ppERK with the two anti-
MEK drugs, we found that the single drugs had the expected 30% level of 
inhibition effect, but administering both drugs simultaneously caused a 35.87% 
level of inhibition effect (Table 4-4, first column), which is little additional 
suppression of ppERK activation, beyond the single drug effect. This 
antagonistic (less than additive) outcome is expected because the two drugs 




















Additive pair  
 
(MKP3_PP2A) 
NorCI = 0.9534  




Wt+drug1+drug2  0.6413  0.4989 0.5423 0.2478 
Mutant1+10%drug1+drug2  0.7032  0.6859 0.6702 0.6435 
Mutant2+ drug1+10%drug2  
0.7032  0.7013 0.6816 0.6194 
DoubleMutant+10%drug1+10%dru
g2  0.9429  0.9343 0.9116 0.9194 
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The proliferation probabilities of the four cell types (sensitive cell, 
mutant1 cell, mutant2 cell, and double mutant cell) in the model are described 
in Table 4-4. Under the different NCE treatments of drug pairs with the same 
single effect, the combined effect is the highest for the synergistic treatment 
(drugs targeting MEK and EGFR), and the lowest for the antagonistic 
treatment (drugs targeting MEK at two different sites).  The drug pairs 
targeting Raf and Grb2 are not in the antagonism dose ratio range, and this can 
be reflected from its normalized CI and their combined effect on ERK 
activation. Therefore the drug pair targeting Raf and Grb2 is excluded from 









Figure 4-12 Evolution patterns of cancer cells under three NCE 
treatments on the pathway with the same single effect 





Antagonistic (redundant), additive and synergistic treatments with the 
same single effects were applied into the pathway. The resistance evolution 
dynamics under these three NCE treatments is described in Figure 4-12. The 
different combined effects were reflected in the initial propagation speeds for 
the sensitive cells among four NCE treatments. Within 100 generations, the 
synergistic treatment allows the sensitive subpopulation to drop fastest among 
the three NCE treatments, thus allowing single and double mutant cells to 
arise earliest. In other words, when cells are under synergistic treatment, 
although there is a larger and faster drop in the sensitive subpopulation at the 
beginning of treatment, the speed at which double mutant cells develop also 
gets larger. After 100 generations, the cell population is mainly composed of 
sensitive cells with antagonistic treatment; in comparison, the cell population 
is composed of a comparable amount of mutant cells and sensitive cells with 
additive treatment; the cell population is mainly composed of single and 
double mutant cells with synergistic treatment. This again shows the speed of 
resistance evolution is higher with synergistic treatment, than that when cells 






Figure 4-13 Statistics on resistance evolution dynamics for cancer cells 
under NCE treatments on the pathway with the same single effect 
Statistics on resistance evolution dynamics for cells treated by drugs with the 
same single effect regarding (A) the time for double mutant cells to arise; (B) 
the total cell number after 50 generations; (C) the total cell number after 100 
generations; (D) the number of double mutant cells after 100 generations. Data 
are presented as mean ± SD obtained from three replicates. 
 
Some statistical data are recorded in Figure 4-13 for comparison 
among different NCE treatments. The time for the double mutant cells to arise 
(arrows, Figure 4-13A) is significantly longer in cancer cells treated with 
antagonistic treatment (55 ± 5 generations), compared to the time for double 
mutant cells to arise in cancer cells with additive (44 ± 2 generations) and 
synergistic (29 ± 2 generations) treatments (unpaired t test, p < 0.05). The 
significant earlier arising time of double mutant cells suggest a possibility of 
earlier resistance evolution in cancer cells with synergistic treatment. 
The total cell number after 50 generations under different NCE 
treatments indicates there is a fast initial drop in the total cell numbers when 
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cells are given a synergistic treatment (Figure 4-13B), but it soon propagates 
to 10
9
 after 100 generations (Figure 4-13C). The DM subpopulation after 100 














 cells)  (unpaired t test, p < 0.05, 
Figure 4-13D). This indicates that, even though synergistic treatment have a 
stronger initial inhibition effect on cancer cell growth, the large composition 
of resistant cells might be problematic for long term therapy. This additionally 
supports that the synergistic treatment accelerates resistance evolution as we 
found in the above experiments. As a result, both the extent and duration of 
cancer cell population drop should be considered in order to determine the true 
advantage. 
 
4.4.5 The disadvantages of synergy towards resistance 
evolution are not dependent on the model of EGFR-ERK 
pathway 
The EGFR-ERK pathway contains many complexities which may 
create confusion when attributing the cause of an effect.  One example of the 
complexity of the EGFR-ERK system is that pairs of inhibitors can change 
their combination efficacy, depending on the doses used and the inhibition 
level compared.    Pairs of drugs can be antagonistic or additive depending on 
dose, and this might create an appearance that a treatment could be 
miscategorized or that our analysis might be inadequate.  We do not believe 
that the complexity of the EGFR-ERK pathway is responsible for the 
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difference in the speed of resistance evolution under synergistic versus 
antagonistic drug treatments.  Indeed, a parallel effect has already been shown, 
with slightly different models of proliferation and evolution, in bacterial 
populations (Hegreness, Shoresh et al. 2008).  To confirm that the difference 
in the speed of resistance evolution is not an artifact of the EGFR-ERK model 
(Figure 4-5, Section 4.4.2), we repeat the simulations of mutant cell evolution, 
using generic proliferation rates instead of ERK-based proliferation rates.  
4.4.5.1 Assumed proliferation rates from simple Michaelis-Menten 
kinetics under treatments with the same single effect 
We assumed a series of proliferation rates according to simple 
Michaelis-Menten kinetics as the input to the evolution model (Table 4-5). In 
this situation, the shapes of the drug dose-effect curves are hyperbolic 
(Method 4.3.8.1). Assumed proliferation rates in this case are based on the 
same single effect, but have different combined effect (Table 4-5).  
The resistance evolution dynamics of cancer cells under four 
hypothesized NCE treatments with the same single effect was shown in 
Figure 4-14. Since the combined effect varies among synergistic, additive, 
antagonistic and super antagonistic treatments, the initial propagation speeds 
for the sensitive cells differ among the four NCE treatments (Figure 4-14, 
purple lines). The synergistic treatment allows the sensitive subpopulation to 
decline the fastest among the four NCE treatments, resulting in the fastest 
single and double mutant cells evolution. The time for double mutant cells to 
start expanding across the whole cell population is positively related to the CI 
of drug pairs: super antagonistic > antagonistic > additive > synergistic, as 
denoted by arrows in Figure 4-14. The black triangles denote the highest 
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intersections of the blue lines and other colored lines, indicating the time when 
the DM subpopulation is largest in the total cell population. The predominance 
of the four NCE treatments based on the time for DM subpopulation to be the 
largest follows the same order: super antagonistic > antagonistic > additive > 
synergistic.  
Therefore, we show that in the absence of the pathway as transduction 
system for drug effect, the difference in the speed of resistance evolution 




Table 4-5 Assumed proliferation rate in simple Michaelis-Menten kinetics with the same single effect 
 
 
Cell type/ Proliferation rate/drug Super antagonistic pair Antagonistic pair Additive pair Synergistic pair 
Wt+drug1+drug2 0.7000 0.6000 0.5000 0.3000 
Mutant1+drug2+10%drug1 0.6864 0.6864 0.6864 0.6864 
Mutant2+drug1+10%drug2 0.6864 0.6864 0.6864 0.6864 
DoubleMutant+10%drug1 
+10%drug2 




Figure 4-14 Evolution patterns of cancer cells under assumed drug 
treatments with the same single effect  
Evolution patterns of cancer cells in pathway independent, simple Michaelis-
Menten kinetics with the same single effect. Simulations are conducted under 
NCE treatments which are (A) super antagonistic; (B) antagonistic; (C) 
additive; (D) synergistic. 
 
4.4.5.2 Assumed proliferation rates from simple Michaelis-Menten 
kinetics under drug pairs with the same combined effect 
A parallel experiment was conducted as a control for investigating 
cancer cell evolution based on a pathway-independent Gompertzian model. A 
series of proliferation rates were assumed according to simple Michaelis-
Menten kinetics as the input to the evolution model (Table 4-6, Method 
4.3.8.2). Assumed proliferation rates in this case simulate NCE treatments 





Table 4-6 Assumed proliferation rate in simple Michaelis-Menten kinetics with the same combined effect 
 
 






Additive pair Synergistic pair 
Wt+drug1+drug2 0.5000 0.5000 0.5000 0.5000 
Mutant1+drug2+10%drug1 0.4821 0.5832 0.6864 0.7915 
Mutant2+drug1+10%drug2 0.4821 0.5832 0.6864 0.7915 
DoubleMutant+10%drug1+10
%drug2 




Evolution patterns of cancer cells in pathway independent, simple Michaelis-
Menten kinetics with the same combined effect. Simulations are conducted 
under NCE treatments which are (A) super antagonistic; (B) antagonistic; (C) 
additive; (D) synergistic. 
 
The resistance evolution dynamics of cancer cells under four 
hypothesized NCE treatments with the same combined effect were shown in 
Figure 4-15. Since the same proliferation rate for sensitive cells was assumed 
in the four hypothesized NCE experiments, the initial propagation speeds for 
the sensitive cells under four NCE treatments are similar (Figure 4-15, 
intersections of purple lines and the black dashed line: x = 50 generations). 
This similar trend in initial propagation of sensitive cells lasts for about 50 
generations. The time for single mutant cells to arise is also similar under 
different NCE treatments. However, the different proliferation rates for single 
mutant cells determine different growth rates for the single mutant 
subpopulation (Figure 4-15, red lines), thus causing differences in the time for 
double mutant cells to arise and evolve. Synergistic treatment allows fully 
Figure 4-15 Evolution patterns of cancer cells under assumed drug 
treatments with the same combined effect 
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resistant cells to appear and grow faster than additive and antagonistic 
treatments (Figure 4-15, arrows).  
This pathway independent simulation is based on proliferation rates 
obtained from assumed drugs with the same combined effect on sensitive cells. 
It therefore serves as a control for the simulations in the system with assumed 
proliferation rates from drug pairs with the same single effect (Section 4.4.5.1) 
and the simulations in pathway-dependent cell evolution system (Section 
4.4.2). It confirms again that the difference in the speed of resistance evolution 
is not an artifact effect from the EGFR-ERK pathway model. 
 
4.4.6 The disadvantages of synergy towards resistance 
evolution are not dependent on the model of cell growth  
In order to describe the dynamics of tumor growing in a confined space 
with limited nutrients, the Gompertzian model has taken into consideration of 
many variables, such as the tumor doubling time will change as the cell 
population increases. The uncertainty of parameters in the Gompertzian model 
increases its complexity, as the parameters may vary considerably for patients 
with even the same type of cancers. Therefore, in order to normalize 
sophisticated parameters in the Gompertzian model, a cancer cell evolution 
model with constant final cell number was built.  This experiment will prove 
that the differences we see in the speed of resistance evolution are not an 
artifact of the Gompertzian assumptions. In the model we use here, the cells 
are growing exponentially with the death rate proportional to the difference 
between cell number at current generation and the threshold (10
12
, Table 4-2). 
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Thus the total cancer cell population will increase to the threshold level 
rapidly within a few generations and remain at the threshold level (Method 
4.3.9). Other details of model are the same with the pathway-dependent 
Gompertzian model developed in Section 4.4.2. There will only be 
transformation and balance among the four component cell types, i.e. sensitive 
cell, mutant 1, mutant 2, double mutant cell.  
 
Figure 4-16 Evolution patterns of cancer cells under four NCE 
treatments in exponential growth model 
Simulations were conducted under treatment of drug pairs that are (A) super 
antagonistic; (B) antagonistic; (C) additive; (D) synergistic. The time for 
double mutants to arise is positively related to the CI of the drug pairs. 
 
Because the total cell number reaches the threshold level after several 
generations, the final cell number cannot be compared. However, we can still 
determine the predominance based on the time for DM subpopulation to 
become the largest cell subpopulation under these four NCE treatments, which 
is: super antagonistic > antagonistic > additive > synergistic (Figure 4-16). 
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This reveals the same information of advantage of antagonistic 
treatment over synergistic treatment provided there are no interferences from 
other parameters, leading to the conclusion that this effect is indeed the 
property of NCE, independent of those parameters in the Gompertzian model.  
 
4.4.7  The evolutionary impact of sequential and 
simultaneous administration schedules for dual inhibition of 
MEK and EGFR  
Combinations of two drugs can be administered simultaneously or 
sequentially. The composition of the combination as well as the order and time 
gap between two drugs can determine whether cancer cells respond or not, and 
can be varied according to the need (McCarthy 2012). A recent experimental 
study on colorectal cancer has shown that EGFR-resistant colorectal cancer 
cells remained under control following sequential treatment with inhibitors 
against EGFR and MEK (Misale, Yaeger et al. 2012).  In this work, cells were 
exposed to EGFR inhibitor cetuximab for more than 3 months. The resistant 
clones developed were then isolated and co-treated with cetuximab and 
selective inhibitors of MEK kinase. During treatment, they were found to be 
sensitive to combinatorial targeting of MEK and EGFR.  In this section, we 





Figure 4-17 A comparative study of simultaneous and sequential 
targeting EGFR and MEK   
The measurements investigated are: (A) the time for double mutant cells to 
arise; (B) the time for double mutant cells to start expanding in the cell 
population; (C) the time to DM dominance. The left bars in all three subplots 
indicate data from simultaneous drug treatment; the middle bars in all three 
subplots indicate data from sequential drug treatment, with the drug 
combination added after EGFR inhibitor-resistant mutant1 cells grow till 10
7
; 
the right bars in all three subplots indicate data from sequential drug treatment, 
with the drug combination added after EGFR inhibitor-resistant mutant1 cells 
grow till 10
8
. Data are presented as mean ± SD obtained from three replicates.   
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Simulations were conducted to compare resistance evolution dynamics 
in cancer cells with EGFR and MEK inhibitors being administrated 
simultaneously and sequentially. For sequential treatment, cells were exposed 
to EC50 dose of EGFR inhibitor first for a certain amount of time, until 




, which corresponds to 1% or 
10% of the initial total cell number. A drug pair targeting MEK and EGFR 
with the same ED50 dose was then added into the cell population. The 
resulting evolution patterns of four cell types under different drug treatments 
are depicted in Figure 4-17.  It takes a significantly longer time for double 
mutant cells to arise and start expanding in cancer cells receiving simultaneous 
treatment of drugs targeting MEK and EGFR than in cancer cells receiving 
sequential drug treatment (unpaired t test, p < 0.05, Figure 4-17A and B). In 
addition, simultaneous treatment allows 2210 ± 26 generations to achieve DM 
dominance. This time to DM domince is significantly longer compared to that 





mutant1 cells (Figure 4-17C). These significant differences in the speed of 
resistance evolution suggest that early initiation of a MEK inhibitor in 
combination with anti-EGFR therapies is a rational strategy for delaying or 








4.5 Conclusions and discussion 
Development of drug resistance mutants has been a major challenge 
during cancer therapy. Combination treatment of cancer with two drugs 
targeting the proliferation-promoting EGFR-ERK pathway are typically used 
to achieve maximum therapeutic effect and for the advantage of lower 
possibility for cells to develop multi-drug resistance.   
In this work, we have built a hybrid model with deterministic single-
cell pathway modeling and stochastic population-level modeling, enabling us 
to investigate population-level behaviors of whole tumors instead of single 
cells. Since the molecular interaction and cell cycle occur in two different time 
scales, i.e. minutes versus days, assumptions were made to simplify and link 
these two biological processes together, based on previous experimental and 
simulation findings (Asthagiri, Reinhart et al. 2000). 
We have done systematic screen for combined targeting of the EGFR-
ERK pathway, and it reveals various drug pairs that are synergistic, additive, 
and antagonistic (Figure 4-2). In particular, the drug pair targeting Raf and 
Grb2 in this pathway shows dose ratio-dependent combination efficacy 
(DRCE). In order to study the NCE-evolution relationship, it is reasonable to 
select a representative pair with different combination efficacies for 
investigation. However, this particular partly antagonistic drug pair in this 
pathway limits the options for antagonistic drug pair and dose ratio selection. 
This causes difficulty for later analysis on the resistance evolution dynamics 
under different NCE treatments with the same single effect. 
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Although researchers have been in favor of exploring synergistic drug 
combinations for the sake of lower drug dosage, through our model, 
synergistic treatment targeting the EGFR-ERK pathway are found to allow 
multidrug resistance to arise and evolve much faster compared to additive and 
antagonistic treatments. This accelerated resistance evolution of cancer cells 
under synergistic treatment was also verified when drugs were added with the 
same single effect on ppERK inhibition. This conclusion on the speed of 
resistance evolution also holds true in subsequent simulations of pathway 
independent drug combination treatments with the same single effect, 
simulations of pathway independent drug combination treatments with the 
same combined effect, and simulations of cancer cells following a simple 
exponential growing rule. This reveals that the qualitative resistance evolution 
dynamics we have observed are robust to variation in our estimates; it is an 
inherent property that the NCE affects the speed of resistance evolution in 
cancer cells.  
Nonetheless, there are still limitations in this study. For example, the 
drug uptake, solubility, specificity of target and non-specific loss are neglected 
in current study, all represented as the constant full initial dose introduced to 
the cell system; a fixed mutation rate is taken from previous studies on 
resistance evolution (Monro and Gaffney 2009), and the same rate for 
mutation to resistance and back mutation to sensitive per cell cycle is assumed. 
More detailed simulations of drug metabolism and varying mutation rate can 
be performed to examine the effect of the mutation rate variation on our 
simulation results and the speed of resistance evolution.  
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Another limitation in this study is that cellular heterogeneity is 
neglected and population data is assumed to reflect the behavior of a 
hypothetical average cell. In other words, it only captures average cell 
dynamics in a cell population, without considering individual cell variation in 
the model formulation. Our preliminary Monte Carlo studies which 
incorporates log-normal distribution of protein initial concentration showed 
that small variations on protein concentrations and pathway parameters do not 
affect the combination efficacy classification (with mean µ= 0, and standard 
deviation σ= 0.01). However, further work on Monte Carlo simulation can at 
least provide a conceptual and practical means to study and understand the 
impact of cell-to-cell variability in protein expression levels on cell fate. 
Conclusions obtained from simulations including the intracellular noise will 
therefore be more realistic and more reliable.  
4.6 Outlook on experimental validation 
This chapter is focused on simulating the role of EGFR/ERK pathway 
in pathological conditions. More specifically, it was analyzed how cancer cell 
population will evolve drug resistance under combination treatments targeting 
the EGFR/ERK pathway. Different drug combination schemes including 
combination targets, dosing ratio, and dosing schedules are applied to target 
the EGFR/ERK pathway, leading to different evolution fitness and selection 
among sensitive and resistant cancer cells. In this section, some future 
experiments are proposed to test the model predictions. 
Combination therapy has been widely employed as a method to 
achieve maximum efficacy and reducing side effects, but experimentally it is 
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difficult to exhaustively test every pair of drugs. Our framework for 
classifying drug pairs according to their combination index is therefore useful 
in making preliminary plan for experimental exploration. The NCE of drug 
pairs targeting species in the EGFR/ERK pathway in HeLa cells can be tested 
experimentally. Single inhibitors used experimentally targeting this pathway 
include: gefitinib and erlotinib inhibiting EGFR, vemurafenib and dabrafenib 
inhibiting Raf, PD98059 and PD184352 inhibiting MEK, etc. 
Synergistic/antagonistic/additive pairs can be checked and validated by 
applying two different single inhibitors together, and examining the ppERK 
expression in the first 10 min through western blot. The standards of additivity 
can be designed as applying the same inhibitors to cells, because two same 
drugs must appear additive. 
A benefit of using mathematical modeling to make predictions is that, 
we could study the cancer system not as a black box, but rather dissect and 
propose a mechanism for evolution process under drug treatment first. 
Combining with experimental validation, we could then go back to revise our 
model and eventually provide the reasonable explanations on mechanisms 
involved. However, it is a big challenge to experimentally study the evolution 
of cancer cells, because of the long doubling time, and very low rate of 
mutation. Therefore, ways of speeding up the evolution process of cancer cells 
such as chemotherapy can be employed in parallel with our combination drug 
treatment experiments. Moreover, we can also use bacteria to mimic cancer 
cell evolution by providing a heterogeneous and nutrition limited cancer-like 
environment. For instance, microfluidic technologies can be used to create a 
location-dependent nutrition levels over a very small volume, thus mimicking 
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the heterogeneous characteristic of cells in a tumor. Such types of experiments 



















Chapter 5 General conclusions and 
outlook 
5.1 Experimental data for systems biology 
The traditional approach of biochemistry and molecular biology has 
shown successful results in identifying pathway components and some 
protein-protein interactions, but is not able to comprehend the emergent 
properties of cell at the systems level. In order to understand how cells 
function as a system, quantitative data on interactions among components in 
protein networks, as well as comprehensive modeling are required.  
Systems biology is an integration of experimental data and theoretical 
models, which usually requires iterative rounds of refinement for the model to 
fit experimental data, and eventually make predictions and give guidance for 
future experiment design. Theoretical modeling helps to design experiments 
being conducted in a more economical way. For example, in Chapter 4, our 
framework for classifying drug pairs can also be applied to several different 
EGFR-ERK pathway models, allowing us to compare and get a list of drug 
pairs consistently predicted as having the same NCE. These predicted drug 
pairs could then be used as candidates for further experimental validations. 
However, conclusions from theoretical models will need confirmation and 
verification from experimental results. 
In this thesis, some initial experimental exploration on investigating 
scaffold protein localization and signal assembly is conducted in the thesis. In 
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particular, through co-localization and co-trafficking studies of scaffold 
proteins and signaling molecules, it provides insights that MP1 and Paxillin 
might localize together at a focal adhesion site to achieve ERK activation and 
focal adhesion assembly during cell spreading. This reveals that single-cell 
measurements based on fluorescent fusion proteins are advantageous for 
small-scale time-resolved systems biological analyses. However, some nodes 
of the network are typically not measurable at the single cell level. 
Bioinformatic analysis, combined with various experimental approaches 
including high throughput data would be useful for providing directions in 
biological research. Motivated by the enlightening experimental data, we use 
an integrated approach incorporating mathematical modeling to build a 
predictive model of cell signaling. 
This thesis is mainly composed of theoretical simulation studies based 
on previous published experimental data and theoretically deduced data, e.g. 
estimation on protein kinetic parameters based on protein similarity (Chapter 
3). It gives insights into the dynamics of signal transduction and regulation of 
cell responses by internal regulators and external drugs. Further work can take 
into consideration that the individual cell variation is needed to generate 
conclusions regarding cell-to-cell variation. Additionally, further experimental 
measurement techniques would be required to verify the conclusions drawn 





5.2 Testing the quantitative model of signal 
sensitivity 
Sensitivities of pathways reflect the capability of a system to react 
against varying environments, and robustness against intracellular as well as 
extracellular perturbations. Using scaffold mediated signaling as an example, 
we have further illustrated that various components in the EGF pathway have 
distinct contributions and response at different steps to signal output with 
varying EGF dosage and time after stimulation. Thus, it is necessary to try to 
understand the ERK dynamics through dissecting the exact contribution of 
these two scaffolds to see if they act in concert or in isolation in activating 
ERK.  
While the actual physiological significance of this multi-level and 
cross-regulation effect remains to be verified experimentally, the current 
model provides an attractive platform to further integrate the input of other 
scaffolds and regulators such as the Sef, GEFs & GAPs (Yamada, Taketomi et 
al. 2004; Sasagawa, Ozaki et al. 2005; Li, Ung et al. 2009) as well as higher 
level of control via scaffold dimerization and the interactions among different 
scaffold proteins. These serve as a regulatory hub to fine-tune ERK signaling 
in response to different fluxes of physiological or pathophysiological stimuli. 
Understanding the intricate interplay and their differences in normal and 
pathophysiological conditions should help shed light on the possible 
mechanism of their involvement in cancer (Faried, Faried et al. 2006; Park, 
Pullikuth et al. 2009), inflammation (Kolesnick and Xing 2004; Yan, John et 
al. 2004), adipogenesis (Kortum, Costanzo et al. 2005), cardiovascular disease 
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(Budzyn, Marley et al. 2006; Shimokawa and Rashid 2007), urinary bladder 
dysfunction (Peters, Schmidt et al. 2006), and in the response to anti-
proliferative agents targeting these proteins and pathways (Takeda, Kondo et 
al. 2006).  
 
5.3 Drug combination therapy for cancer 
cell resistance evolution 
It is often claimed that systems biology will simplify drug discovery by 
enabling for in silico identification of potential drug targets (Assmus, Herwig 
et al. 2006). Using EGFR-ERK pathway as an example, we have done 
systematic screening for combined targeting of the EGFR-ERK pathway, and 
it reveals various drug interaction types including synergism, additivity, and 
antagonism.   
In our stochastic cancer cell resistance evolution model, synergistic 
drug pairs targeting the EGFR-ERK pathway is found to allow the multidrug 
resistance to arise and evolve much faster compared to additive drug pairs and 
antagonistic drug pairs, especially in cancers with low turnover rate. This non-
intuitive conclusion conflicts with previous favoritism of synergistic drug 
pairs’ exploration. Therefore, the selection of drug combination schemes 
might require the consideration of balancing between the resistance evolution 




While the actual physiological significance of the NCE remains to be 
verified experimentally, the current model on resistance evolution dynamics 
provides a possible opinion on selection of drug combination. In contrast to the 
traditional strategy of seeking synergistic drug pairs, it proposes a selection of 
two antagonistic drugs targeting the EGFR-ERK pathway when combating 
cancer cells. This work also provides a platform for further investigation in 
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